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Summary 
 
Collagens are a superfamily of glycoproteins mainly found in the extracellular 
matrix. They are the most abundant proteins in the human body. Collagens 
are characterized by a right handed triple helix formed out of three left-
handed α-chains representing repeats of the motif G-X-Y, where (hy-
droxy)proline and (hydroxy)lysine are often found at positions X and Y. To act 
as a functional collagen, selected hydroxylysine residues have to be further 
modified by the addition of either galactose or the disaccharide glucosylga-
lactose. This glycosylation of collagen takes place in the endoplasmic reticu-
lum before the formation of the triple helix and is mediated by specific β(1-O) 
galactosyl- and α(1-2) glucosyltransferase enzymes. The molecular nature of 
these glycosyltransferases has remained unknown to date. The present 
study describes the identification of collagen galactosyltransferase enzymes 
using a strategy based on affinity chromatography and protein sequencing by 
mass spectrometry. Three structurally related candidate genes were cloned 
and expressed in Sf9 insect cells using the baculovirus system. Two of the 
three candidate glycosyltransferases (GLT25D1 and GLT25D2) were con-
firmed to be active collagen galactosyltransferases. The collagen galactosyl-
transferase genes are differentially expressed in human tissues, suggesting 
that these enzymes may show preference for different types of collagens or 
contribute to the varying extent of collagen glycosylation throughout tissues. 
This was supported by showing a selective preference of GLT25D1 and 
GLT25D2 for collagen type III and collagen type IV acceptors. GLT25D1 
showed a higher enzymatic activity on deglycosylated collagen type I to type 
V than GLT25D2. 
Collagen glycosylation is conserved in animals and collagen is also found in 
several prokaryotic genomes. Proteins sharing structural similarity with the 
collagen galactosyltransferases have been found in prokaryotes and even in 
virus. The Acanthamoeba polyphaga mimivirus has been detected as an 
unique member of the nucleo-cytoplasmic large DNA virus family being 
clearly a virus but also showing features never seen before in viruses. 
Mimivirus is the largest known DNA virus with a 1.2 Mbp linear dsDNA ge-
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nome. It was reported that mimivirus encodes eight proteins with a collagen 
triple helix motif. These collagens are most probably found in the fibrils of the 
virus capsid. These fibrils cover the whole icosahedral virus capsid, which 
are specific for mimivirus. As the Gram staining of mimivirus is positive, it is 
supposed that the viral fibrils are glycosylated. This suggests that the mimivi-
ral collagens might be post-translationally modified by hydroxylation and sub-
sequent glycosylation.  
In this study, the protein L230 was identified as a mimiviral collagen gluco-
syltransferase transferring glucose on the acceptor hydroxylysine on animal 
and on mimiviral collagens. This addition of glucose on the acceptor hy-
droxylysine in collagen has not been reported up to now. It seems that colla-
gen glycosylation in mimivirus is different than in animal collagens.  
In conclusion, this work reports the identification and characterization of the 
two human collagen galactosyltransferases GLT25D1 and GLT25D2 and the 
identification of the mimiviral collagen glucosyltransferase L230. 
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Zusammenfassung 
 
Kollagene sind Glykoproteine, die hauptsächlich in der extrazellulären Matrix 
vorkommen und sind daher die am häufigsten vorkommenden Proteine im 
menschlichen Körper. Kollagene haben eine charakteristische rechts dre-
hende tripel-helikale Struktur. Diese Helix wird aus drei links drehenden α-
Ketten aufgebaut, welche aus dem repetitiven Sequenzmotif Gly-X-Y beste-
hen. Häufig stehen an den Positionen X und Y (Hydroxy)Prolin oder 
(Hydroxy)Lysin. Damit das Kollagen funktionell aktiv sein kann, muss es mit 
Galaktose oder Glukosylgalaktose post-translationell modifiziert werden. 
Diese Kollagen Glykosylierung findet im Endoplasmatischen Retikulum statt 
bevor die Tripel-Helix gebildet wird und wird von einer spezifischen β(1-
O)Galactosyltransferase und einer α(1-2)Glucosyltransferase durchgeführt. 
Diese beiden Glykosyltransferasen waren bis heute noch nicht bekannt. 
Diese Arbeit beschreibt die Identifizierung dieser Kollagen Galaktosyltransfe-
rasen, welche mit Hilfe einer Affinitätschromatographie und anschliessender 
Proteinsequenzierung mittels Massenspektroskopie identifiziert werden 
konnten. Daraufhin wurden drei strukturell verwandte Kandidatengene klo-
niert und mittels Bakuloviren in Sf9 Insektenzellen exprimiert. Zwei der drei 
gefundenen Kandidaten (GLT25D1 und GLT25D2) zeigten in einem Aktivi-
tätstest eine Kollagen-Galaktosyltransferase-Aktivität. 
Die Kollagen Galaktosyltransferasen sind in menschlichen Geweben unter-
schiedlich exprimiert. Dies lässt vermuten, dass diese Enzyme eine Präfe-
renz für verschiedene Kollagen Typen zeigen könnten, oder dass sie dazu 
beitragen, dass die Kollagene in den verschiedenen Geweben verschieden 
stark glykosyliert werden. Diese Vermutung wurde bestärkt indem gezeigt 
wurde, dass GLT25D1 und GLT25D2 präferentiell Kollagen Typ III und Kol-
lagen Typ IV glykosylieren. GLT25D1 hingegen zeigte eine höhere enzymati-
sche Aktivität auf deglykosyliertem Kollagen Typ I bis Kollagen Typ V als 
GLT25D2.  
Kollagen Glykosylierung in Tieren ist ein stark konservierter Prozess. Kolla-
gen selbst findet man jedoch nicht nur in höheren Lebewesen, sondern auch 
in verschiedenen prokaryontischen Organismen. Daher ist es nicht erstaun-
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lich, dass auch Proteine mit strukturellen Ähnlichkeiten zu den Kollagen Ga-
laktosyltransferasen in Prokaryonten und sogar in Viren gefunden wurden. 
Ein Beispiel dafür ist das Acanthamoeba polyphaga Mimivirus. Es ist ein ein-
zigartiges Wesen, das auf der einen Seite klar ein Virus ist, jedoch auf der 
anderen Seite auch charakteristische Merkmale hat, die nie zuvor in Viren, 
gefunden worden sind. Mit einem 1.2 Mbp grossen linearen doppelsträngigen 
DNS Genom ist das Mimivirus das grösste bekannte DNS Virus. Es wurde 
berichtet, dass das Mimivirus acht Proteine kodiert, welche ein Tripel-Helix 
Kollagen Motiv haben. Diese Kollagene findet man mit grosser Wahrschein-
lichkeit in den Fibrillen auf dem Viruskapsid. Die für das Mimivirus spezifi-
schen Fibrillen bedecken das ganze ikosahedrische Viruskapsid. Die Gram-
Färbung des Mimivirus ist positiv, was darauf hindeutet, dass die mimiviralen 
Kollagene durch Hydroxylierung und anschliessende Glykosylierung post-
translationell modifiziert werden.  
In dieser Arbeit wurde das Protein L230 als mimivirale Kollagen Gluko-
syltransferase identifiziert. Wir konnten zeigen, dass L230 die Übertragung 
von Glukose auf den Hydroxylysin-Akzeptor sowohl in tierischen als auch in 
mimiviralen Kollagenen katalysiert. Dieser Transfer von Glukose auf den 
Hydroxylysin-Akzeptor in Kollagen wurde bis jetzt noch nicht beschrieben. 
Daraus lässt sich schliessen, dass sich die Kollagen Glykosylierung im Mimi-
virus von der Kollagen Glykosylierung in Tieren unterscheidet. 
Zusammenfasst zeigt diese Arbeit die Identifizierung und Charakterisierung 
der zwei humanen Kollagen Galaktosyltransferasen GLT25D1 und GLT25D2 
sowie die Identifizierung der mimiviralen Kollagen Glukosyltransferase L230.  
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1 Introduction 
1.1 Glycosylation 
Glycosylation is the most prevalent posttranslational modification. Glycosyla-
tion represents the addition of carbohydrates to aglycons like proteins and 
lipids, thereby leading to the formation of glycoconjugates. These glycocon-
jugates consist either of monosaccharides, oligosaccharides or polysaccha-
rides, which are attached through a glycosidic bond.  
Protein glycosylation is a highly diverse process and gives rise to a large di-
versity in structural complexity. Even though mammals only use nine distinct 
monosaccharides for glycan biosynthesis (Figure 1), the diversity in glycosy-
lation exceeds the diversity achieved by other post-translational modifications 
by far. The multiple glycosidic linkages applicable and the branched nature of 
glycan chains contribute largely to the diversity of glycoconjugates. 
 
 
Figure 1: Haworth Projection of the Nine Mammalian Monosaccharides. The chemical 
structure of the nine human monosaccharides is shown. 
 
1.1.1 Glycan Structure and Conformation 
Although the theoretical number of carbohydrate combinations is astronomi-
cal, some rules of biosynthesis apply, thereby restricting the repertoire of gly-
coconjugates to specific classes. The basic monosaccharide units used in 
mammals are six carbon sugars (hexoses) with the exception of Xylose (Xyl), 
which has five carbons (pentose) and sialic acid (Sia), which has nine carbon 
atoms. Four of the six carbon atoms of the hexose are chiral centres, be-
cause they have four chemically different substituents. The substituents 
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around the chiral centre the farthest away from the carbonyl group of the gly-
can can be arranged in two different stereochemical ways. These stereoi-
somers are named D- and L-form enantiomers, due to their inability to be 
converted in each other (mirror images). In contrast, D-glucose (Glc) and D-
galactose (Gal) are epimers. They only differ in the stereochemical configu-
ration of the carbon number 4 (C4).  
The monosaccharides are linked via a glycosidic bond through C1 and a hy-
droxyl group of another monosaccharide. C1 has four chemically different 
substituents and is therefore a chiral centre referred to as anomeric carbon 
atom. The two possible configurations (anomers) at the anomeric C1 are the 
α and the β configurations (Figure 2). The structure of a disaccharide is given 
by its monosaccharide constituents and its linkage. For example lactose is 
described as Galβ(1-4)Glc where the C1 of Gal is glycosidically linked to the 
C4 of Glc in a β-linkage.  
 
 
Figure 2: Glycosidic Linkages. The glycosidic linkage can be in an α or in a β conforma-
tion. An α(1-6) and a β(1-3) linkage are shown. 
 
1.1.2  Glycoconjugate Classification 
Seven classes of glycosylation have been described to date. The main form 
of protein-bound glycans, the N-glycans, is linked to the amino group of an 
asparagine residue. O-glycans are linked to the hydroxyl group of serine (S), 
threonine (T) or hydroxylysine (Hyl) residues (Figure 3). The five additional 
glycosylation classes represent C-glycans, which are linked through an un-
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usual C-C bond to a tryptophane (W) residue (1, 2), the glycosaminoglycans 
(GAG), which are linked to a serine, the GPI anchor, which consists of phos-
phatidylinositol (PI) linked to the glycans, the glycolipids, which are linked to 
ceramide and the cytoplasmic and nuclear glycosylation forms, which repre-
sents GlcNAc bound to serine or threonine. 
 
N
Glc
NAc
Glc
NAc
ManMan
Man
N-glycan
S/T S/T S/T S/T Hyl
Man
Gal
NAc
O-glycans
GalFuc Glc
W
C-glycan
Man
S
GAG
Xyl
Gal
Gal
PI
GPI anchor
GlcN
Man
Man
Man
Glycolipids
Cer Cer
GalGlc
Gal
S/T
Cytoplasmic/nuclear
glycans
Glc
NAc
 
Figure 3: Classification of the Glycoconjugates in Mammals. Shown are the seven 
classes of glycosylation. N, S, T and W stand for the amino acids asparagine, serine, 
threonine and tryptophane. PI is phosphatidylinositol and Cer stands for ceramide.  
 
1.1.2.1 N-Glycosylation 
Asparagine (N)-linked glycosylation is the best understood glycosylation 
pathway. The synthesis comprises several steps which can be grouped into 
three major stages. The process is initiated by the formation of a lipid-linked 
oligosaccharide (LLO), followed by an en bloc transfer to the nascent poly-
peptide in the sequence Asn-X-Ser/Thr, where X can be every amino acid 
except proline, and is terminated by a final processing of the oligosaccharide. 
The elongation of the lipid carrier dolichol takes place at the membrane of the 
endoplasmic reticulum (ER). The first five monosaccharide units are added at 
the cytosolic side of the ER membrane. After flipping to the luminal side of 
the membrane, the LLO assembly proceeds with the sequential addition of 
nine monosaccharides (Figure 4). The complete structure Glc3Man9GlcNAc2 
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is co-translationally transferred en bloc by the oligosaccharyltransferase on 
an asparagine residue of a nascent polypeptide. After transfer on proteins, 
glucosidases remove two of the three terminal Glcs. The third Glc is impor-
tant for the quality control cycle in the ER and is removed during this process 
(3, 4). Correctly folded proteins carrying Man8GlcNAc2 glycans are further 
transported to the Golgi apparatus, where N-glycans are further trimmed 
down and elongated (for further details on N-glycosylation see review (3)). 
While the N-glycans leaving the ER always have the same structure, the gly-
cosylation steps in the Golgi result in a tremendous diversity of N-linked gly-
cans. 
 
 
Figure 4: Scheme of N-Glycosylation. N-glycosylation starts on the cytosolic side of the 
ER with the assembly of the LLO Man5GlcNAc2 which is then flipped into the lumen of the 
ER. Glc3Man9GlcNAc2 is transferred on the nascent polypeptide followed by the removal of 
the three terminal Glcs by ER-glucosidases. Man8GlcNAc2 is transported to the Golgi where 
further trimming and subsequent modifications of the oligosaccharide take place.  
 
1.1.2.2 O-Glycosylation 
In contrast to N-glycosylation where oligosaccharides are transferred en bloc 
to proteins, O-linked glycosylation is initiated by the transfer of single mono-
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saccharides. The most common O-glycan is a GalNAc (5-7) linked to the hy-
droxyl group of either serine or threonine, known as the Tn-antigen, which is 
then further elongated with other monosaccharides. This type of O-linked 
glycosylation takes place in the Golgi apparatus (8). The other types of O-
linked glycosylation begin in the ER. To these groups belong O-linked Fuc 
and Glc, added in the ER, which are found in a specific consensus sequence 
in the epidermal growth factor-like (EGF) and thrombospondin domains (9). 
Additionally, O-linked mannose on serine or threonine is synthesized in the 
ER (8, 10). Glycosylation is not confined to the organelles of the secretory 
pathway. A reversible glycosylation implying O-linked GlcNAc is also found in 
the cytoplasm and in the nucleus (11). Finally, a type of O-linked glycosyla-
tion is specific to the collagen domain. This O-linked addition of Gal or of the 
disaccharide Glc-Gal is discussed in chapter 1.2.4.2. 
1.1.3 Glycosyltransferases 
The synthesis of glycans is mediated by glycosyltransferase enzymes (GT). 
GTs catalyze the formation of glycosidic linkages to either connect two sug-
ars or a sugar with an aglycon. GTs use activated monosaccharides as donor 
substrates. This activation is achieved by binding to nucleotides or to doli-
chol-phosphate. Typical nucleotide-activated sugars are UDP-Gal, GDP-Man 
or CMP-Sia.  
 
NDP-sugar + acceptor NDP + acceptor-sugar
Glycosyl-
Transferase
NDP-sugar + acceptor-sugar NDP + acceptor-sugar-sugar
Glycosyl-
Transferase  
Figure 5: Glycosyltransferase Reaction. Activated nucleotide sugars are hydrolyzed by 
the glycosyltransferase, catalyzing the formation of a glycosidic linkage and the release of 
NDP (nucleotide diphosphate) or in the case of CMP-Sia the release of NMP (nucleotide 
monophosphate). 
 
After synthesis in the cytosol and in the nucleus (CMP-sialic acid), nucleo-
tide-sugars are transported across the membrane into the lumen of the ER or 
the Golgi via dedicated transporters (Figure 6) (12). After entering the ER or 
the Golgi compartment, the donor substrates are transferred by the GT onto 
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their respective acceptor substrate, resulting in the release of the nucleotide. 
Nucleotide-monophosphate leaves the lumen in exchange with the incoming 
nucleotide-sugar (13). GDP-Man and UDP-Glc can also be converted to doli-
chol-phosphate-Man and dolichol-phosphate-Glc at the ER membrane.  
 
 
 
 
Figure 6: Nucleotide Sugar Transport Model. NDP-sugars are imported in the lumen of 
the ER/Golgi in exchange with NMP. In the lumen, the glycosyltransferase hydrolyzes the 
NDP-sugar. NDP is converted to NMP and inorganic phosphate (Pi) which leave the com-
partment.  
 
The nucleotide transporters capable of transferring GDP-Fuc and UDP-Gal 
into the ER have not been characterized yet. This is controversial to the fact, 
that O-fucosylation of EGF domains in proteins (9) and galactosylation of hy-
droxylysines in collagen (see chapter 1.2.4.2) take place within the ER. Al-
though no such transporter has been reported in the ER up to now (Table 1), 
there must be a mechanism to import GDP-Fuc and UDP-Gal into the ER as 
it was shown that these glycosylation steps take place in this compartment.  
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Table 1: Distribution of Currently Characterized Nucleotide Sugar Transporter in the 
ER and in the Golgi (according to (7, 12, 14)) 
 
Nucleotide Sugar Donor ER Golgi 
CMP-Sia - + 
GDP-Fuc - + 
GDP-Man - + 
UDP-Gal - + 
UDP-Glc + + 
UDP-GalNAc + + 
UDP-GlcNAc + + 
UDP-Xyl + + 
UDP-GlcA + + 
 
GTs are grouped into families according to their substrate- and linkage-
specificities. The linkage catalyzed is usually mentioned in the name of the 
GT enzymes. For example a β(1-4)-galactosyltransferase catalyzes the for-
mation of the glycosidic linkage in a β conformation of the C1 anomeric car-
bon of Gal with the C4 hydroxy group of the acceptor substrate.  
1.1.4 Defects in the Human Glycome 
The glycome, defined as all glycans synthesized in an organism, is as large 
as the proteome. Several glycosylation pathways are required for a normal 
development and physiology of an organism. Defects in glycosylation path-
ways have various impacts on biological functions. Accordingly, glycosylation 
defects are at the origin of several diseases in humans (Table 2).  
A large family of diseases called congenital disorders of glycosylation (CDG) 
is linked to the N-glycosylation pathway. Two forms can be distinguished, 
CDG type-I with defects in the assembly of the LLO or in the transfer to the 
proteins while CDG type-II is caused by defects of N-glycan trimming within 
the ER or of glycan elongation within the Golgi apparatus (15, 16). More pa-
tients are affected by O-glycosylation linked diseases than N-glycosylation 
linked diseases. Diseases in the O-glycosylation pathway occur mainly in the 
O-xylose and the O-mannose glycosylation pathways. An example for an O-
linked glycosylation disease is the Walker-Warburg Syndrome. This syn-
drome is characterized by mutations in the O-mannosyltransferase, which 
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transfers O-mannose on α-dystroglycan. Also the O-glycans on collagen may 
be important and it is likely that defects in the collagen glycosyltransferases 
could lead to an extracellular matrix disease (see also chapter 1.2.4.2).  
 
Table 2: Representative Selection of Human Diseases Caused by Defects in 
Glycosylation Synthesis Pathways 
 
Human Disease Affected Enzyme/Pathway 
CDG type-I defect in LLO assembly or glycan transfer to proteins 
CDG type-II defects of N-glycan trimming in ER or elongation of glycan in Golgi 
Mucolipidosis II and III lack of mannose-6-phosphate  
Congenital muscular 
dystrophies O-mannose glycans on α-dystroglycan 
Tn Syndrome erythrocytes express Tn antigen 
Paroxysmal nocturnal 
haemoglobinuria defect in GPI anchor 
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1.2 Collagen 
The glycoprotein collagen is the most abundant protein in the animal king-
dom. It represents about one third of all proteins in the human body and is 
found in all tissues. Collagens are particularly abundant in bone, cartilage, 
tendon, ligaments, skin and the walls of blood vessels. By now, at least 44 
genes coding for 29 types of collagen have been identified (17-19). Beside 
collagens, several other proteins, which do not belong to the collagen family, 
have a collagenous domain in their sequence. 
Functionally, collagens are involved in the maintenance of the structure of 
different tissues, they are involved in cell adhesion and organogenesis or 
they regulate tissue repair in wound healing (20, 21). Even fragments of 
collagen, such as endostatin, can work as bioactive peptides (22).  
1.2.1 Collagen Structure 
The collagen molecule is composed out of three left handed α-chains, which 
coil around each other to form a right handed triple helix (Figure 9). Collagen 
molecules can consist of either three identical or different α-chains forming 
homotrimeric (e.g. collagens type II and III) or heterotrimeric structures (e.g. 
collagen type I), respectively. Collagens are characterized by at least one 
collagenous domain represented by the repetition of the triplet glycine-X-Y, 
where X and Y are often the amino acids proline and lysine. The presence of 
glycine in every third position is essential for the helical configuration, as gly-
cine is the only amino acid which is small enough to fit into the centre of the 
helix. At their extremities collagen molecules contain non-triple helical do-
mains, the N- and C- propeptides.  
1.2.2 Collagen Nomenclature 
Collagen types are numbered with Roman numerals in the order of their dis-
covery. The α-chains are numbered with Arabic numerals with the collagen 
type indicated in parenthesis. For example, α1(III) stands for the α1 chain of 
type III collagen. The genes encoding collagen proteins are named by the 
prefix COL followed by the Arabic number for the chain, the ′A′ which stands 
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for the α-chain and the Arabic number for the chain. Accordingly, COL1A2 
encodes the α2 chain of collagen type I. 
The collagen superfamily can be subdivided into two major classes based on 
their structure and supramolecular organization: the fibril-forming collagens 
and the non-fibrillar collagens (Figure 7). 
 
 
 
Figure 7: Molecular Organization of Collagens. Four representatives of the collagen 
superfamily are shown: fibril-forming collagen, FACIT, and the network-forming collagens, 
type IV and type VIII. 
 
1.2.2.1 Fibril-forming Collagens 
Fibril-forming collagens are the most abundant type of collagen, representing 
about 90 % of all collagens. The classical fibril-forming collagens comprise 
type I, II and III as well as type V and XI collagens. The latter are classified 
as fibril-forming collagens on the basis of their homology to collagen type I-III.  
The fibril-forming collagens are characterized by the ability to form su-
pramolecular aggregates with a characteristic structure. They form 300 nm 
long unbranched fibrils with a triple helical domain of about 1000 amino ac-
ids, a highly conserved non-collagenous C-terminus and a variable non-colla-
genous N-terminus. At the electron microscopic level, a characteristic band 
pattern with a periodicity of about 67 nm, the so called D-period, is seen in 
the collagen fibrils (Figure 11) (20). 
The molecules are synthesized as procollagens which are large precursor 
molecules containing large non-collagenous N- and C-propeptides linked to 
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the triple helical domain by the short non-collagenous telopeptides. These 
telopeptides are the sites where the intermolecular cross-linking for the colla-
gen fibril stabilization takes place. This results in the formation of quarter-
staggered structures (23). This collagen structure provides the mechanical 
strength of the body in the skeleton, skin, blood vessels, nerves and the in-
testines.  
1.2.2.2 Non-fibrillar Collagens 
Collagens that do not form collagen fibrils belong to the family of non-fibrillar 
collagens, which include type IV and type VI-X collagens for example. This 
group is largely heterogeneous in its structural diversity, tissue distribution, 
macromolecular organization and function. A common feature of these colla-
gens is that non-collagenous sequences are interrupting the collagenous 
domain. 
Non-fibrillar collagens are further divided in different subgroups. For example 
the FACIT, the fibril associated collagens with interrupted triple helices (e.g. 
types IX, XII, XIV, XVI, XIX), are characterized by short triple helical domains 
interrupted by non-collagenous sequences and associate as single mole-
cules with large collagen fibrils. They can act as molecular couplers that or-
ganize and anchor fibrils with other extracellular matrix molecules (21). Fur-
thermore, network-forming collagens, like the collagens type IV, VIII and X, 
form the essential scaffold of basement membranes. The transmembrane 
collagens (types XIII, XVII, XXIII, XXV) function both as cell surface receptors 
and as extracellular matrix components (24). Finally, multiplexins, such as 
collagen types XV and XVIII, contain multiple triple helical domains with sev-
eral interruptions and are also found in basement membranes (21).  
1.2.2.3 Non-collagenous Proteins 
As mentioned previously, the collagenous domain is not confined to colla-
gens, but is also found in several other proteins, such as the hormone adi-
ponectin (ADIPOQ) (25), the mannose-binding lectin (MBL) (26), the C1q 
complement protein (27), the COLQ subunit of the acetylcholine esterase 
complex (28) and the surfactant proteins SP-A and SP-D (26).  
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Figure 8: Non-collagenous Proteins. A schematic trimeric subunit with the N-terminal, 
collagen-like, neck and CRD domain is shown. Three MBL subunits associate and form the 
high oligomeric MBL molecule. Four subunits associate to form the SP-D molecule.  
 
ADIPOQ is a hormone secreted from adipose tissue and is involved in Glc 
metabolism and fatty acid catabolism (29). It is composed of a signal peptide 
and three domains, namely a variable region, a collagenous domain and a 
globular domain. Through its collagenous domain, ADIPOQ can assemble in 
several oligomeric isoforms, the trimeric, hexameric and the high molecular 
weight (HMW) oligomeric complexes. The collagenous domain of ADIPOQ 
contains four hydroxylated lysine residues, which are glycosylated. These 
glycans play a crucial role in building the HMW complexes. Additionally, the 
hydroxylysines and the glycans might enhance the secretion of the HMW 
ADIPOQ (29). 
MBL, SP-A and SP-D belong to the collagen containing C-type lectins called 
collectins. Their primary structure is organized in four domains: a short N-
terminal, a long collagen-like, a neck and a carbohydrate recognition domain 
(CRD) (Figure 8). The cysteine containing N-terminus contributes to disul-
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phide bond dependent oligomerization between monomers. The collagen-like 
domain forms a triple helix, which is associated with oligomerization and 
maintenance of the molecular structure. The neck domain forms a short 
trimeric coiled coil, which links the collagen-like domain to the CRD. Finally, 
the globular structure at the C-terminus comprising the CRD mediates cal-
cium dependent ligand-binding (30, 31). All collectins have a mannose-type 
CRD (30, 32). 
MBL is synthesized in the liver and is secreted into the blood stream where it 
has an important function in the innate immune system (33, 34). It binds to 
carbohydrates through its CRD. MBL is an oligomeric molecule made up of 
three polypeptides. Through the formation of a collagen triple helical struc-
ture, three polypeptides form a so called subunit. Several subunits can form 
higher oligomeric structures through disulphide bonds (35). In the case of 
MBL, three subunits are required to form the nascent protein (Figure 8). The 
lung surfactant proteins SP-A and SP-D are hydrophilic collagenous proteins 
(36). Lung collectins recognize and interact by their CRD with a wide range of 
carbohydrates on microbial surfaces (37). The collagen-like domain interacts 
with receptor molecules present on various immune cells to initiate clear-
ance. In the case of SP-D, four subunits (Figure 8) form the nascent protein, 
while SP-A has an hexameric structure, in which six subunits oligomerize to 
form the nascent protein (36-38). 
1.2.3 Collagen Biosynthesis 
Collagen biosynthesis is a very complex process with the involvement of 
many intra- and extracellular proteins. Many of these associated proteins are 
unique to collagen.  
Procollagen α-chains are synthesized on the ribosomes of the rough ER 
(Figure 9). As all of the collagen molecules are secreted, collagens are syn-
thesized with a signal peptide which is cleaved within the ER lumen. After 
removal of the signal peptide, several proline and lysine residues are hy-
droxylated by three prolyl-4-hydroxylases (39), one prolyl-3-hydroxylase (40) 
and three lysyl hydroxylases (41, 42). 4-Hydroxyproline is essential for the 
folding and stability of the collagen helix. Hydroxylysines are involved in the 
formation of cross-links and they can also serve as acceptor sites for carbo-
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hydrates which are added by a collagen galactosyl- und glucosyltransferase. 
Most of these modifications occur co-translationally, but continue post-trans-
lationally until triple helix formation prevents further modifications (43).  
 
 
 
Figure 9: Collagen Biosynthesis: The polypeptides of the collagen molecule are synthe-
sized on the ribosomes of the rough ER. In the ER lumen, the molecule is modified and 
forms a triple helix which is transported to the Golgi and which is finally secreted into the 
extracellular matrix where the propeptides are cleaved. Several of the resulting collagen 
molecules associate and form a fibril.  
 
The folding of the procollagen into a triple helix is initiated by the assembly of 
three left handed α-chains at their C-propeptides after complete translocation 
into the lumen of the ER. Since the collagen types are defined on the basis of 
their composition with different α-chains, it is very important, that the correct 
three α-chains associate to form the fibril. This type specific assembly of indi-
vidual α-chains is assured by the C-propeptides of the procollagen molecule. 
The association of the C-propeptides is stabilized by intermolecular disul-
phide bonds. 
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The 250 amino acids long C-propeptides are non-collagenous sequences, 
which show a high homology to each other. They all contain one N-glycan 
and eight cysteine residues. Four of these cysteine residues are located 
within the N-terminus of the C-propeptide and form intermolecular disulphide 
bonds, while the four C-terminal located cysteines form intramolecular disul-
phide bonds (44, 45) (Figure 10). The three α-chains begin to twist around 
each other propagating the formation of the triple helix towards the N-termi-
nus (46). The propagation of the helix formation is done in a zipper-like man-
ner. One single cell can simultaneously express several types of collagen. 
For example, skin fibroblasts synthesize the very homologous but genetically 
distinct collagens type I, III and V. It has to be assured that the different pro-
collagen chains are able to discriminate from each other and assemble in a 
type specific manner. A discontinuous sequence of 15 hydrophilic amino ac-
ids in the C-propeptide has been shown to direct procollagen self-association 
in a type specific manner (47).  
 
triple helical domain
C ‐telopeptide
C-propeptide
 
Figure 10: Schematic Representation of the C-propeptide Domain. Each polypeptide 
forms two intramolecular disulphide bonds in its C-terminal C-propeptide, whereas four in-
termolecular disulphide bonds are formed in the N-terminal region of the C-propeptide. 
 
After completion of the triple helix formation, procollagen molecules are 
transferred to the Golgi apparatus, where they form aggregates by staggering 
and are secreted into the extracellular matrix (48-50). This transport of 
procollagen from the ER to the Golgi involves the chaperone HSP47, which 
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associates with the triple helical collagen in the ER and dissociates within the 
Golgi due to the pH shift. It has been suggested that HSP47 could stabilizes 
correctly folded collagen triple helix intermediates and to control lateral ag-
gregation of collagen molecules (51, 52).  
Currently, it is not fully resolved how procollagen molecules are transported 
through the secretory pathway. The size of the classical ER-Golgi transport 
vesicles is 60-80 nm. These vesicles seem to be too small to contain procol-
lagen which has a length of 300 nm. Latest studies showed that the transport 
of procollagen shares some common features with well studied proteins as 
the vesicular stomatitis virus membrane protein ts-O45-G in ER-Golgi trans-
port, but also differs considerably at the molecular level (53). It has been pro-
posed that procollagen leaves the ER at sites devoid of COPII coat, although 
it appears that COPII is required for ER exit (53). Later, during transit through 
the Golgi, procollagen does not need to leave the lumen of the Golgi cister-
nae via vesicular carriers (54). 
In the extracellular matrix, procollagen molecules are processed to collagen. 
The N- and C-propeptides are cleaved by propeptidases leading to the for-
mation of the mature collagen molecule. Collagen self associates into higher 
fibrillar supermolecules in which each molecule is displaced about one-quar-
ter of its length along the axis of the fibril (20, 55) (Figure 11). Finally, the 
collagen molecules are cross-linked between each other or within the colla-
gen molecule. 
 
300 nm
40 nm
D-period
67 nm  
Figure 11: Supramolecular Assembly of Fibril-forming Collagen. In the quarter-stag-
gered form each collagen molecule is displaced about one-quarter of its length to form a 
collagen fibril. Each fibril-forming collagen molecule has a length of 300 nm. The gap which 
separates consecutive molecules is 40 nm causing the characteristic appearance of the col-
lagen fibril with a D-period of 67 nm. Intermolecular cross-links are shown by lines. 
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1.2.4 Collagen Modifications 
The biosynthesis of collagen involves many posttranslational modifications 
that precede triple helix formation. Several ER resident specific enzymes are 
involved in this process.  
1.2.4.1 Hydroxylation  
Some proline and lysine residues of the collagen polypeptide are hydroxy-
lated. This modification is only performed on collagen α-chains as further 
modifications are prevented by the triple helical structure of the final collagen 
(56-59). In the hydroxylation reaction, three different enzymes are involved: 
the lysyl hydroxylase (LH), the prolyl-4-hydroxylase (P4H) and the prolyl-3-
hydroxylase (P3H). These three enzymes belong to the family of 2-oxogluta-
rate dioxygenases, which require Fe2+, O2, 2-oxoglutarate and ascorbate for 
their activity. In the reaction, 2-oxoglutarate is decarboxylated to succinate. 
One oxygen atom of O2 is then incorporated into succinate, the second one 
being incorporated into the newly formed hydroxy group of hydroxylysine or 
hydroxyproline (Figure 12).  
 
 
 
Figure 12: Collagen Hydroxylation: The three reactions of collagen hydroxylation are 
shown. These reactions are catalyzed by different collagen hydroxylases, the prolyl-3-hy-
droxylase (P3H), the prolyl-4-hydroxylase (P4H) and the lysyl hydroxylase (LH).  
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The catalytically critical Fe2+ binding residues are two histidines and one 
aspartate, which are conserved in all 2-oxoglutarate dioxygenases (60). 
 
1.2.4.1.1 4-Hydroxyproline 
The P4H catalyzes the formation of 4-hydroxyproline (4Hyp) in the sequence 
Gly-X-Pro in collagen and several other proteins with collagenous domains. 
In vitro the enzyme does not act on the single amino acid acceptor proline. It 
needs a minimal sequence requirement, which is fulfilled by the triplet -X-Pro-
Gly-. It is absolutely necessary that proline is flanked by at least one amino 
acid on each side (61). 4Hyp stabilizes the collagen triple helix by H-bonds 
with water molecules, which is an essential process for the stability and fold-
ing of the collagen triple helix (57). These water-mediated H-bonds link the 
hydroxylgroup of 4Hyp with the carbonyl group of either glycine within the 
same chain or with 4Hyp in the adjacent chain (62).  
The collagen P4H is a α2 β2 tetramer. The catalytical active site is located 
within the α subunit, while the β subunit contains a disulfide isomerase (PDI) 
activity. It was shown that the monomeric subunits do not possess any hy-
droxylase activity by themselves (59, 60, 63).  
Three different isoenzymes exist for the α subunit, namely type-I ([α(I)]2 β2), 
type-II ([α(II)]2 β2) and type-III ([α(III)]2 β2) P4H (64-67). Type-I and type-II 
P4H show very similar but not identical enzymatic properties (65). Type-I 
P4H is the main form in most cell types, type-II is the major form in chondro-
cytes, osteoblasts and endothelial cells, while type-III is expressed in many 
human tissues, but at a much lower extent than type-I and type-II, respec-
tively (64, 68, 69).  
The β subunit with the PDI activity catalyzes the formation of disulfide bond 
formation in the C- and N-propeptides of procollagen. The main function of 
the PDI subunit associated with P4H is to keep the insoluble α subunit in an 
active, non-aggregated conformation and to retain the enzyme within the lu-
men of the ER (70). 
The production of a stable P4H enzyme in vivo requires the co-expression of 
collagen polypeptides. This was demonstrated by expressing both subunits 
of the P4H in the yeast Pichia pastoris, which has no endogenous P4H activ-
Introduction 
23 
ity. Most part of the recombinantly expressed P4H subunits were unassem-
bled, a finding that could be prevented by coexpression of collagen type-III 
(71). A possible explanation could be that the tetramer becomes rapidly 
dissociated in its subunits in the absence of collagen. This dissociation pre-
vents the consumption of 2-oxoglutarate, O2 and ascorbate. Collagen syn-
thesis appears to have a mutual control mechanism: stable production of 
P4H depends on collagen expression while stable collagen triple helix forma-
tion depends on proper P4H function. 
1.2.4.1.2 3-Hydroxyproline 
The collagen P3H catalyzes the formation of 3-hydroxyproline (3Hyp) in col-
lagen. As 3Hyp is dependent on the presence of 4Hyp, 3Hyp is found in al-
most all collagens in the sequence Gly-3Hyp-4Hyp-Gly (72, 73). This sug-
gests that the main substrate sequence for the P3H is Gly-Pro-4Hyp-Gly. The 
largest amount of 3Hyp is found in collagen types IV and V. 3Hyp is much 
less frequent than 4Hyp in the total amino acid content of collagen and its 
expression varies among the different collagen types (40). 
P3H was originally reported as leprecan, a chondroitin sulphate proteoglycan 
(74) and later as growth suppressor GROS1 (75). Sequence analysis re-
vealed three proteins which are closely related in human, mouse and 
chicken, called P3H1, P3H2 and P3H3. P3H1 is found in an intracellular col-
lagen modification complex together with the cartilage-associated protein 
(CRTAP) and cyclophilin B (40, 76). It is found in tissues, in which fibril-form-
ing collagens are expressed. The other two P3H family members P3H2 and 
P3H3 might have different substrate specificities. Based on an assay using 
labelled procollagen as a substrate, it was shown that the chicken P3H1 ex-
hibits P3H activity (40) in vitro.  
The function of 3Hyp is not well understood. Recent investigations have 
shown that P3H1 is crucial for bone development and collagen helix forma-
tion. Cabral et al (77) studied lethal to severe osteogenesis imperfecta-like 
bone dysplasia patients which do not show any collagen type I mutation. 
Their P3H1 mRNA (also called LEPRE1 mRNA) level was markedly de-
creased and the protein was absent. Different mutations in the LEPRE1 gene 
were identified. The absence of P3H1 in these patients affects folding of col-
Introduction 
24 
lagen type I. As folding is delayed, the molecule is exposed for a longer time 
to the lysyl hydroxylase and the P4H which results in over-modified collagen 
type I. The overmodification of the collagen may suggest that P3H1 functions 
as a collagen chaperone. These data delineate a new recessive bone disor-
der caused by deficiency of P3H1 called osteogenesis imperfecta type VIII 
(77, 78).  
1.2.4.1.3 5-Hydroxylysine 
LH catalyzes the formation of 5-hydroxylysine in collagen domains by the 
hydroxylation of lysines found in the Y position of the triplet G-X-Y. The non-
helical C- and N-telopeptides with the sequence X-K-A or X-K-S are also hy-
droxylated on lysine residues (79). Hydroxylation of lysine residues is a typi-
cal modification of collagen. The extent of lysyl hydroxylation varies in differ-
ent collagen types. Also, the same collagen type can be differently lysyl hy-
droxylated in different tissues. Hydroxylysines have two important roles: first 
they are essential for the formation of stable intra- and intermolecular cross-
links and secondly they serve as acceptor sites for carbohydrates. Lysyl hy-
droxylation is only possible before the collagen triple helix is formed (72). 
The LH family comprises the three different isoenzymes LH1, LH2 and LH3 
(42, 80-82). Further variation occurs by alternative splicing of LH2, leading to 
a short and a long form of the enzyme, the LH2a and LH2b, respectively. The 
identity between LH1 and LH2 is 75 % while LH3 shares 59 % identity with 
both LH1 and LH2. Phylogenetic analysis revealed that the LH isoforms de-
rive from one ancestral gene by two duplication events. LH1 and LH2 which 
share a higher level of sequence identity result from a more recent duplica-
tion than LH3 which appears to be the ancestral gene (83). 
The LH1 isoform is expressed in many tissues such as skin, lung, placenta, 
cartilage, spleen, brain and liver (84). It was shown that the enzyme carries 
two N-glycans of which one is important as its mutation leads to a drastic re-
duction of the LH activity (85). Mutations in LH1 cause Ehlers Danlos Syn-
drome VIa (see chapter 1.2.5.1). 
LH2 is a specific collagen telopeptide lysyl hydroxylase, whereas all three 
isoenzymes are able to hydroxylate lysine residues in the collagenous do-
main (86). As mentioned above, LH2a is the short and LH2b the long form. 
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LH2b has an additional exon which results in additional 21 amino acids. 
LH2a is the major form and expressed in several organs as pancreas, pla-
centa, liver, heart, kidney and spleen (80, 87). Mutations in the gene coding 
for LH2 have been associated with the Bruck syndrome (see chapter 
1.2.5.3). 
The LH3 enzyme is mainly expressed in the heart, pancreas and the pla-
centa (42). Up to now no disease could be attributed to mutations in the LH3 
gene located on chromosome 7q36 (42, 88). LH3 knock-out mice die at 
embryonic day 9.5 (89). Unlike LH1 and LH2, LH3 has been reported to be a 
triple active enzyme and to exhibit beside its LH activity also two additional 
enzyme functions, namely a collagen galactosyl- and glucosyltransferase 
activity (90, 91). These activities have been mapped to the N-terminal do-
main of the enzyme while the LH activity is located in the C-terminus.  
Like the prolyl hydroxylases, the lysyl hydroxylases belong to the 2-oxogluta-
rate dioxygenase family and require Fe2+, O2, 2-oxoglutarate and ascorbate. 
The active LH enzyme is a homodimer and is a peripheral membrane protein 
located in the ER lumen, although no ER retrieval signal is found (82, 92). 
Unlike the soluble prolyl hydroxylases, LH is membrane bound (93).  
1.2.4.2 Collagen Glycosylation 
The O-glycosylation of collagen has been first described by Grassmann and 
Schleich in 1935 (94). Collagen carries either the monosaccharide Gal or the 
disaccharide Glc-Gal which are glycosidically linked to the C5-hydroxygroup 
of hydroxylysine. The structure of the glycan was determined by Spiro in 
1967 as being Glc(α1-2)Gal(β1-O)Hyl (95) (Figure 13). Gal and Glc are 
transferred by either the collagen galactosyltransferase (ColGalT) or the 
collagen glucosyltransferase (ColGlcT), respectively. The ColGalT transfers 
Gal from UDP-Gal to the hydroxylysine of procollagen but not to free hy-
droxylysine (96). ColGlcT transfers Glc from UDP-Glc to galactosylated hy-
droxylysine. These reactions are dependent on the bivalent cofactor Mn2+ 
(97). 
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Figure 13: Glycan of Collagen: Structure of the Glc(α1-2)Gal(β1-O) disaccharide attached 
to a hydroxylysine residue of collagen. 
 
Since glycosylated hydroxylysines were found on the nascent collagen poly-
peptide chain, it was concluded that collagen glycosylation already starts co-
translationally (98, 99). Collagen glycosylation ceases after completion of the 
triple helix formation. This indicates that only collagen α-chains, but not triple 
helical collagen can serve as a substrate for the ColGalTs (100, 101). A free 
ε-amino group of the hydroxylysyl residue and a nonhelical polypeptide con-
formation are absolute requirements for both collagen glycosyltransferases 
(21). 
The extent of collagen glycosylation varies in different types of collagen, but 
also in the same type of collagen in different tissues (90). It is known that 
type IV collagen is the most glycosylated collagen, whereas collagen type I 
carries only very little amount of carbohydrates (97). The function of these 
carbohydrates is unknown. Carbohydrates appear to influence both the lat-
eral packing of the collagen molecule into fibrils and the diameter of the fibrils 
in fibril-forming collagens (102). The collagen domain of ADPIOQ and MBL 
also carry glycosylated hydroxylysine residues, which are important for the 
oligomerization and proper secretion of these proteins (25, 103). 
Myllylä and coworkers described in the years 2000 and 2002 for the first time 
that the collagen lysyl hydroxylase LH3 shows low glucosyl- (91) and galacto-
syltransferase (90) activities. However these ColGalT and ColGlcT activities 
are so low that they might have little biological significance (104). There is 
further evidence that there must exist two additional enzymes responsible for 
most of the collagen glycosylation in vivo as previous data showed that the 
two reactions are catalyzed by two different enzymes in vertebrates (63, 100, 
105). In LH3, the catalytically active site of the collagen glycosyltransferase is 
Introduction 
27 
comprised within the N-terminal region of the protein, whereas the LH activity 
is mediated by the C-terminal region of the protein (104). The glycosyltrans-
ferase domain contains a DxD motif which is known to bind to divalent metal 
ions and to the hydroxyl group of the ribose moiety. Mutating the motif 
causes inactivation of the collagen glycosyltransferase activities of the LH3 
enzyme (90, 106).  
LH3 knock-out and LH3 transgenic mice with a mutated LH activity domain 
but with intact collagen glycosyltransferase activities were generated (107). 
These mice serve as a good model to study the importance of collagen gly-
cosylation linked with the LH3 triple active enzyme. By studying the LH3 
knock-out embryos it was observed that the total collagen amount (both intra- 
and extracellular) decreased. Due to the impaired secretion machinery, col-
lagen type IV aggregated which lead to a dilatation of the ER and to a con-
densed Golgi. The secretion of the normally highly glycosylated collagen type 
IV was further studied in fibroblasts of the knock-out mice. Collagen type IV 
aggregates within the ER due to deficient glycosylation and is rapidly de-
graded within the cell which leads to a lower amount of collagen type IV 
compared with wildtype fibroblasts. Sipilä et al suggested that collagen type 
IV might aggregate due to incorrect folding, which could result due to the lack 
of glycans (108). The highly glycosylated network-forming collagen type VI is 
unique among collagens as it forms tetramers already inside the cells (109). 
In knock-out fibroblasts no tetramers could be detected demonstrating the 
important function of the glycans in collagen type VI tetramerization. How-
ever, in fibroblasts of LH3 transgenic mice with a mutated LH activity domain, 
normal tetramerization and secretion but abnormal aggregation and distribu-
tion of type VI collagen was detected (108). These results suggest that colla-
gen glycosylation plays an important role in collagen folding and quality con-
trol of the proteins as seen for the N-glycans. Furthermore, the glycans ap-
pear to be involved in the formation of supramolecular collagen structures. 
1.2.4.3 Collagen Cross-linking 
The mechanical strength of collagen fibrils depends on the highly regulated 
mechanism of covalent intermolecular cross-link formation. Collagens are 
crosslinked through a reaction of aldehydes, which are generated from lysine 
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or hydroxylysine residues by the extracellular enzyme lysyl oxidase and the 
lysyl oxidase-like enzymes (110). The cross-links connect non-helical telo-
peptides with helical regions in adjacent collagen molecules. The formation of 
the cross-link begins with a step catalyzed by the lysyl oxidase, which 
oxidatively deaminates the ε-amino group of the telopeptide lysine or hy-
droxylysine to the corresponding reactive lysylaldehyde and hydroxylysylal-
dehyde, respectively. The subsequent steps occur spontaneously. The alde-
hydes are involved in the formation of various cross-links, either by aldol 
condensation of two aldehydes or by condensation of an aldehyde and an ε-
amino group of a second lysine, hydroxylysine or glycosylated hydroxylysine. 
Hydroxylysine-derived cross-links are more stable than those formed by ly-
sine aldehydes. The lysine aldehyde pathway occurs mainly in adult skin, 
cornea and sclera, whereas the hydroxylysine aldehyde pathway occurs in 
bone, cartilage, ligament and embryonic skin (111). 
1.2.5 Diseases Related to Collagen Biosynthesis Defects 
Collagens are susceptible to acquire mutations which can lead to a variety of 
diseases of bone, cartilage or blood vessels. This is due to the high amount 
of invariant and essential glycine residues. Substitution of either of the first 
and second nucleotide positions in the codon for glycine GGN leads to an 
amino acid exchange on the protein level. This exchange leads to a change 
of the triplet G-X-Y, which is fatal, as no other amino acid will fit into the cen-
tre of the collagen helix. Additionally, collagens contain many exons which 
could be skipped while the gene is processed (21). 
According to the National Institute of Arthritis and Musculoskeletal and Skin 
Diseases (NIAMS) (http://www.niams.nih.gov/) there are currently more than 
200 heritable disorders of the connective tissue linked with mutations in col-
lagen or collagen processing genes (112). 
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Table 3: Examples for Human Collagen Diseases 
 
Affected Gene Human Disease 
COL3A3, COL4A4, COL4A5, COL4A6 Alport Syndrome 
COL6A1, COL6A2, COL6A3 Bethlem Myopathy 
LH2 Bruck Syndrome 
COL5A1, COL5A2 Ehlers Danlos Syndrome Type I,II 
COL3A1 Ehlers-Danlos Syndrome Type IV 
COL18A1 Knobloch Syndrome 
COL1A1, COL1A2 Osteogenesis Imperfecta 
P3H1 Osteogenesis Imperfecta Type VIII 
 
1.2.5.1 Ehlers Danlos Syndrome 
The family of Ehlers Danlos Syndromes (EDS) is a heterogeneous group of 
connective tissue disorders which are clinically characterized by fragility of 
the skin, hypermobility of the joints and hyperextensibility. The syndrome is 
named after the Danish dermatologist Edvard Ehlers and the French derma-
tologist Henri-Alexandre Danlos (113). The disorder can be inherited auto-
somal dominantly, autosomal recessively or X-linked according to their differ-
ent subtypes. Based on the “Villefranche Nosology, 1997” six major classes 
of EDS are known based primarily on the molecular defects (114). The esti-
mated prevalence is 1 in 5′000 individuals depending on the type of EDS 
(115). 90 % of all EDS cases represent EDS type I or type II and are there-
fore called classical type. The defect is caused by mutations in the collagen 
type V gene. The cause of type III is unknown. EDS type IV is caused by 
mutations in the collagen type III gene while mutations in the collagen type I 
gene lead to EDS type VIIa and VIIb. These types of EDS are autosomal 
dominant. Another subtype of EDS type VII, named EDS type VIIc is caused 
by the mutation of a collagen processing enzyme, the N-propeptidase. EDS 
type VI, also called kyphoscoliotic type of EDS, is an autosomal recessive 
disease which is biochemically divided into two subgroups: type VIa: with a 
low activity of LH1, due to mutations in the LH1 gene, and type VIb with a 
normal LH activity. Up to now, the cause of EDS VIb is not known. The major 
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symptoms of patients suffering from EDS type VI are progressive kyphosco-
liosis, muscular hypotonia, joint laxity, scleral fragility and rupture of the ocu-
lar globe (21). 
 
Table 4: EDS Types and their Causes 
 
EDS Type New Nomenclature Affected Gene 
EDS Type I Classical Type COL5A1, COL5A2 
EDS Type II Classical Type COL5A1, COL5A2 
EDS Type III Hypermobile Type COL3A1, TNXB (tenascin-XB) 
EDS Type IV Vascular Type COL3A1 
EDS Type V Other Types X-linked, cause unknown 
EDS Type VI Kyphoscoliotic Type VIa: LH1 VIb: cause not known 
EDS Type VII Arthrochalasic Type VIIa, VIIb: COL1A1, COL1A2 
EDS Type VIIc Dermatosparactic Type ADAMTS2 (N-propeptidase of collagen type I and II) 
 
1.2.5.2 Osteogenesis Imperfecta 
Osteogenesis Imperfecta (OI), also known as brittle bone disease is a auto-
somal dominant genetic disorder. It is mainly characterized by bone fragility 
and fractures. The disease can be accompanied by reduced life span, bone 
deformities, blue sclera, hearing loss and other evidence of connective tissue 
abnormalities. The phenotypic presentation varies from mild to lethal. For the 
classification of OI, a scheme developed by Sillence and colleagues is used. 
The patients are classified by radiographic, genetic and clinical criteria and 
are assigned to one of the four groups, namely type I to IV (112). Three new 
uncommon types of OI have been described and assigned as OI type V to 
type VII (116-118). The cause of these OI types is unknown, but they do not 
show any mutations in the genes coding for COL1A1 and COL1A2. As type V 
to type VII show OI phenotype but no collagen type I mutation, it has been 
proposed to call them “syndromes resembling OI” (119).  
Mutations in COL1A1 and COL1A2 account for 85 % of all OI cases. More 
than 250 distinct mutations are known. Most of them are single nucleotide 
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substitutions that exchange a glycine to another amino acid, thus resulting in 
a reduced collagen stability (120). The mildest form of OI (type I) is caused 
by mutations that generate a premature stop codon within the COL1A1 gene. 
Due to the silencing of one allele, the total amount of collagen is diminished 
as the transcripts of the altered collagen are unstable and undergo nonsense 
mediated RNA-decay (112). 
1.2.5.3 Bruck Syndrome 
The Bruck syndrome (BS) is an autosomal recessively inherited disorder. 
The disease is characterized by osteoporosis, joint contractures at birth, 
short stature and fragile bones. Often seen are also recurrent fractures of 
bones in infancy and early childhood, features reminiscent of OI (21). The 
biochemical analysis of bone in BS patients revealed an underhydroxylation 
of the telopeptides of collagen type I, but normal hydroxylation in the triple 
helix. LH2 is the lysyl hydroxylase which hydroxylates lysine residues in the 
telopeptide region of the collagen molecule. BS type II is defined by patients 
having mutations in the LH2 found on chromosome 3q23-q24 while BS type I 
is linked with mutations within chromosome 17p12 (86, 121, 122). This 
classification is based on genetic data as there are no phenotypic differences 
(86, 122).  
1.2.5.4 Scurvy 
Scurvy was a very common disease among sailors. The cause of scurvy is 
the inability of human beings to synthesize ascorbic acid within the liver be-
cause the last enzyme in the cascade to convert Glc to ascorbic acid is 
missing. Therefore, ascorbic acid has to be taken up by nutrition. Insufficient 
intake of ascorbic acid will result in scurvy. All mammals except Man, some 
monkeys and guinea pigs, are able to synthesize ascorbic acid in their liver 
(123). Only the above listed animals will develop scurvy if deprived of ascor-
bic acid in their diet.  
Insufficient intake of ascorbic acid results in an impaired collagen biosynthe-
sis. As ascorbic acid is a cofactor of the prolyl- and lysyl hydroxylases, the 
absence of ascorbic acid and thus the absence of hydroxyproline and hy-
droxylysine leads to unstable collagen polypeptides which are not able to 
self-assemble into triple helices. These instable collagen molecules lead to 
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haemorrhage of the gum and thus loss of teeth, poor wound healing, bruising 
and hyperkeratosis (124, 125). Scurvy can be prevented by a diet which in-
cludes citrus fruits and vegetables which are good sources of ascorbic acid. 
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Abstract 
Collagen is a trimer of three left-handed alpha-chains representing repeats of 
the motif Gly-X-Y, whereas (hydroxy)proline and (hydroxy)lysine residues 
are often found at positions X and Y. Selected hydroxylysine are further 
modified by the addition of galactose and glucose-galactose units. Collagen 
glycosylation takes place in the endoplasmic reticulum before triple helix 
formation and is mediated by β(1-O)galactosyl- and α(1-2)glucosyltransfe-
rase enzymes. We have identified two collagen galactosyltransferases using 
affinity chromatography and tandem-MS protein sequencing. The two colla-
gen β(1-O)galactosyltransferases corresponded to the GLT25D1 and 
GLT25D2 proteins. Recombinant GLT25D1 and GLT25D2 enzymes showed a 
strong galactosyltransferase activity towards various types of collagen and 
towards the serum mannose-binding lectin MBL, which contains a collagen 
domain. Amino acid analysis of the products of GLT25D1 and GLT25D2 
reactions confirmed the transfer of galactose to hydroxylysine residues. The 
GLT25D1 gene is constitutively expressed in human tissues, whereas the 
GLT25D2 gene is only expressed at low levels in the nervous system. The 
GLT25D1 and GLT25D2 enzymes are similar to CEECAM1, to which we 
could not attribute any collagen galactosyltransferase activity. The GLT25D1 
and GLT25D2 genes now allow addressing the biological significance of col-
lagen glycosylation and the importance of this post-translational modifica-
tion in the etiology of connective tissue disorders. 
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Introduction 
Collagens are the most abundant proteins in the human body. To date, 29 
types of collagen have been described, which are encoded by at least 44 
genes (20, 36, 44). Collagens are characterized by domains representing re-
peats of the triplet Gly-X-Y, where proline and lysine are often found at the 
positions X and Y. The Gly-X-Y repeats are not confined to collagens, but are 
also found in several proteins, such as the hormone adiponectin (28), the 
mannose-binding lectin (MBL) (10), the C1q complement protein (34), the 
COLQ subunit of the acetylcholine esterase complex (4) and the surfactant 
proteins SP-A and SP-D (10).  
After synthesis in the endoplasmic reticulum (ER), three procollagen sub-
units associate to build a right-handed triple helix. However, before the for-
mation of the triple helix structure, the nascent procollagen polypeptides 
undergo several post-translational modifications. These modifications com-
prise the hydroxylation of selected proline (19) and lysine (32) residues, 
which are catalyzed by three prolyl-4-hydroxylases (16), one prolyl-3-
hydroxylase (45) and three lysylhydroxylases (42). Hydroxylysine can be 
further modified by the addition of the monosaccharide Gal(β1-O) or the dis-
accharide Glc(α1-2)Gal(β1-O) (38). 
Whereas the glycosylation of collagen has been first described by Grassmann 
and Schleich in 1935 (9) and the structure of the glycan determined by Spiro 
in 1967 as being Glc(α1-2)Gal(β1-O)Hyl (39), the molecular nature of the 
collagen glycosyltransferase enzymes has remained elusive up to now. Col-
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lagen galactosyltransferase (ColGalT) and glucosyltransferase activities have 
been characterized using partially purified proteins (23, 30, 31), which ap-
peared to be instable. Recently, the lysylhydroxylase-3 LH3 enzyme has been 
shown to catalyze a modest galactosyl- and glucosyltransferase activity, sug-
gesting that this enzyme is a combined hydroxylase and glycosyltransferase 
(11). 
Prolyl and lysyl hydroxylation contribute to the stability of the collagen triple 
helix whereas hydroxylysine is essential for the cross-linking of collagen 
molecules, thus ensuring the strength of collagen fibrils (27). By contrast, the 
biological significance of collagen glycosylation is still unclear. The collagen 
domain of adiponectin and mannose-binding lectin also carry glycosylated 
hydroxylysine residues, which appear important for the oligomerization and 
proper secretion of these proteins (6, 28). 
The importance of collagen post-translational modifications is reflected by 
the diseases caused by defective collagen modifying enzymes. Mutations of 
the LH1 lysylhydroxylase-1 gene lead to the connective tissue disorder Eh-
lers-Danlos syndrome type VI (13) and mutations in the LH2 lysylhydrox-
ylase-2 gene lead to the Bruck syndrome (43). The deficiency of the prolyl-3-
hydroxylase-1 gene causes a severe form of osteogenesis imperfecta (5). The 
availability of the collagen glycosyltransferase genes will enable the compre-
hensive investigation of this post-translational modification in cellular and 
animal models and possibly in human diseases. 
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Materials and Methods 
Affinity chromatography. Collagen glycosyltransferases were enriched by 
affinity chromatography as described by Myllyla et al. (1, 21, 23). Briefly, 10-
day-old chicken embryos were homogenized in 225 mM mannitol, 75 mM 
sucrose, 50 μM DTT and 50 mM Tris-HCl, pH 7.4 at 4 °C and centrifuged at 
15,000 x g for 40 min. Supernatants were filtered and proteins precipitated in 
60 % (NH4)2SO4. The pellets obtained after 20 min centrifugation at 15,000 x g 
were dissolved in 0.2 M NaCl, 50 μM DTT, 1 % glycerol, 20 mM Tris-HCl, pH 
7.4 and dialyzed overnight against 2.5 l of enzyme buffer (0.15 M NaCl, 
10 mM MnCl2, 50 M DTT, 1 % glycerol, 50 mM Tris-HCl, pH 7.4). The 
chicken protein extracts were loaded on a column of agarose-bound bovine 
achilles collagen type I fragments as described previously (31). The column 
was washed with 5 volumes of enzyme buffer containing 500 μM UDP fol-
lowed by elution with 0.1 % acetic acid. Collected fractions were immediately 
neutralized with 1 M Tris pH 8.0. 
 
MS peptide analysis. The eluted fractions from the affinity chromatography 
were desalted and concentrated with Amicon Ultra 10 cartridges (Millipore). 
Portions of 2 μg protein were reduced in 0.6 M Tris pH 8.5, 50 mM DTT for 
5 min at 80 °C and alkylated for 40 min at RT in the dark by the addition of 
iodoacetamide (Sigma-Aldrich, final concentration 200 mM) and desalted by 
adding 9 volumes of ice cold methanol for 18 h on ice. Alkylated proteins 
were digested for 18 h at 37 °C with 0.01 μg trypsin (Roche). ZipTip (Milli-
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pore) purified peptides were then analyzed by liquid chromatography-MS. 
The desalted peptide digest was adjusted to 0.2 % formic acid, 3 % ACN and 
directly injected onto a custom packed 80 mm x 0.075 mm ProntoSil-Pur C18- 
AQ, 3 μm, 200 Å, column (Bischoff GmbH, Leonberg, Germany), connected 
to a LTQ-ICR-FT mass spectrometer (Thermo Scientific, Bremen, Germany). 
The peptides were eluted with a binary gradient of solvents A (3 % ACN, 
0.2 % formic acid) and B (80 % ACN, 0.2 % formic acid) using an Eksigent-
Nano-HPLC system (Eksigent technologies, Dublin, USA). The column was 
flushed for 16 min at a flow rate of 500 nl/min with 100 % buffer A. Buffer B 
was increased to 3 % over 5 min, to 60 % over 50 min, to 100 % over 3 min 
and held at 100 % for 7 min. During gradient elution, the flow rate was 
maintained at 200 nl/min. The mass spectral data were acquired in the mass 
range of 300-2000 m/z. Data dependent MS/MS spectra were recorded of up 
to four of the most intense ions with higher charge state than 1+ using colli-
sion-induced dissociation (CID). Target ions already selected for MS/MS 
were dynamically excluded for 60 s. Peptide signals exceeding 500 counts 
were subjected to CID with normalized collision energy of 32 %. MS and 
MS/MS data were searched using Mascot Server 2.1 (Matrix Science, Lon-
don, UK) as the search engine. Modifications used include carbamidome-
thylation (Cys, fixed) and oxidation (Met, variable). The monoisotopic 
masses of +2, and +3 charged peptides were searched with a peptide toler-
ance of 2 ppm and MS/MS tolerance of 0.8 Da. MS/MS spectra were 
searched against the UniRef100 20051018 database (2764545 sequences; 
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1015909965 residues) downloaded from the European Bioinformatics Insti-
tute (http://www.ebi.ac.uk/uniprot/database/download.html) and the 
Gallus gallus predicted proteins database from the Ensemble Genome 
Browser ftp://ftp.ensembl.org/pub/current_chicken/data/fasta/pep/Gal-
lus_gallus.WASHUC1.jul.pep.abinitio.fa.gz,August 2005).  
 
Cloning and protein expression. The GLT25D2, LH3 and MBL cDNAs were 
purchased from the RZPD repository (Berlin, Germany). The GLT25D1 and 
cerebral endothelial cell adhesion molecule-1 (CEECAM1) cDNAs were cloned by 
RT-PCR from human fibroblast total RNA using the primers 5'-ATCTGAAT-
TCCCTTTAAGGCGCGGCCAGAGTC-3', 5'-ATGTCTAGATGGAGCCTGG-
GCCACCGATG-3' for GLT25D1, and 5'-CGTAGAATTCGAGAGCTCCGGG-
GGCCGCT3', 5'-GACTATCTAGAGTAGTGGCCTGCTCCTGGAC-3' (Micro-
synth, Switzerland) for CEECAM1. The RT-PCR products were subcloned as 
EcoRI-XbaI fragments into the pFastBacI baculovirus transfer vector (Invitro-
gen). The MBL cDNA was subcloned into the EcoRI site of the pFmel-protA 
vector (47) to yield a protein-A fusion protein. The corresponding 732 bp 
MBL fragment was amplified with the primers 5’-ATCGAATT-
CATGGTGGCAGCGTCTTACTC-3’ and 5’-ATCGAATTCAGGAGGGCCTG-
AGTGATATG-3’. Recombinant baculoviruses were produced in S. frugiperda 
Sf9 cells as described previously (12). Protein-A tagged MBL was co-ex-
pressed together with LH3, purified from the supernatant of infected Sf9 
cells by IgG Sepharose chromatography (47) and subsequently used as accep-
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tor for the enzymatic activity assay. The expression of the recombinantly 
expressed enzymes was analyzed on a 10 % Coomassie SDS-PAGE gel. Prior 
to loading on the gel proteins were enriched by concanavalin-A lectin Se-
pharose beads (Amersham). Protein bands were excised from the Coomassie 
SDS-PAGE gel, in gel digested with trypsin according to Shevchenko et al 
(33) and analyzed by LC-MS (procedure see MS peptide analysis section). 
 
Preparation of ColGalT acceptors. Achilles collagen type I, bovine nasal 
septum collagen type II, human placenta collagen type III, IV and V (Sigma) 
were deglycosylated by trifluoromethane sulfonic acid (TFMS)-mediated 
cleavage (7, 37). Acceptor proteins (50 μg) were lyophilized followed by an 
incubation in a dry ice/ethanol bath for 20 min. Proteins were dissolved in 
50 μl TFMS/toluene (16.6:1, v:v) (Sigma-Aldrich). Reactions were subse-
quently incubated at -20 °C for 24 h, then neutralized with 150 μl pyri-
dine/H2O (2:1, v:v) in the dry ice/ethanol bath followed by 15 min incuba-
tion on ice. The sample was mixed with 400 μl 50 mM ammonium acetate 
and dialyzed overnight against 2.5 l of 50 mM ammonium acetate. 
 
Collagen glycosyltransferase assays. Baculovirus infected Sf9 cells were 
lyzed in 1 % Triton-X100 / TBS pH 7.4 for 10 min on ice and postnuclear su-
pernatant was used as enzyme source. Collagen was heat denatured for 
10 min at 60 °C in sodiumacetate pH 6.8 and rapidly cooled down to 0 °C 
before use. Assays were performed with 10 μl of Sf9 postnuclear supernatant 
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in a final volume of 100 μl containing 0.5 mg/ml collagen acceptors, 60 μM 
UDP-Gal or UDP-Glc, 50,000 cpm UDP-[14C]Gal or UDP- [14C]Glc (GE 
Healthcare), 10 mM MnCl2, 20 mM NaCl, 50 mM MOPS pH 7.4, 1 mM DTT. 
Reactions were incubated for 3 h at 37 °C and stopped by the addition of 
500 μl of ice cold 5 % TCA / 5 % phosphotungstic acid. Enzymatic activity 
assays for Km analysis were performed as described above but with different 
amounts of either collagen or UDP-Gal as a substrate for the reaction.  
 
Amino acid analysis. The reaction products of the collagen galactosyltransfe-
rase assays were hydrolyzed in 4 M NaOH for 72 h at 105 °C and the result-
ing single amino acids were derivatized with Fmoc according to Bank et al. 
(2). RP-HPLC (LaChrom Hitachi, Merck) of single amino acids was per-
formed on a ODS Hypersil column, 150 x 3 mm, 3 μm particle size (Thermo 
Electron Corporation) at 40 °C. The galactosylated Hyl (GHyl) and galac-
tosyl-glucosylated Hyl (GGHyl) standards were kindly provided by Ruggero 
Tenni (University of Pavia) (41). Amino acids were separated at a flow rate of 
0.2 ml/min using a gradient elution (Table A2) with the solvents 0.5 M citric 
acid, 5 mM (CH3)4NCl, pH 2.85 (A); 80 % of 20 mM sodium acetate trihy-
drate, 5 mM (CH3)4NCl, pH 4.5, 20 % of methanol (B); 100 % of ACN (C). Ra-
diolabelled [3H]Val and [14C]Tyr (Moravek Biochemicals and Radiochemi-
cals, USA) were used as internal standard. Radioactivity was counted in a β-
counter (Tri-Carb 2900TR, Packard). 
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Northern blotting. The Northern Blot probes were synthesized by PCR using 
the following primers: GLT25D1 upper: 5'-GATGAGGCCGAGAGCTTC-
ATGC-3', lower: 5'-GCATGAAGCTCTCGGCCTCATC-3' (Microsynth, Swit-
zerland), giving a product of 676 bp; GLT25D2 upper: 5'-AAGCAGGCATC-
CAGATGTACC-3' lower: 5'-TCCAGCTGAGCCTGGTCAATG-3' giving a 
product of 559 bp; CEECAM1 upper: 5'-GTGGATGGCTGGATGCTCAAC-3' 
lower: 5'-GACTATCTAGAGTAGTGGCCTGCTCCTGGAC-3' giving a 
product of 785 bp. GLT25D1, GLT25D2 and CEECAM1 cDNA probes were 
labeled with α[32P]dCTP (Hartman Analytic, Germany) by random priming 
(Stratagene). Multiple human tissue RNA arrays (MTE array 3, BD Bioscience 
and First Choice Northern Human Blot 1, Ambion) were prehybridized with 
QuikHyb® hybridization solution (Stratagene) containing 100 μg/ml ultra 
pure herring sperm DNA (Invitrogen) for 1 h at 65 °C, then hybridized with 
5 x 105 cpm of each labeled probe overnight at 65 °C. The arrays were 
washed in 0.1 x SSC, 0.1 % SDS up to 60 °C and exposed on BioMax XAR film 
(Kodak) for 24 h at -80 °C.  
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Results 
ColGalT identification. Most glycosylation pathways have been characte-
rized at the molecular level over the past decades. However, the genes en-
coding the glycosyltransferases involved in the glycosylation of Hyl in colla-
gen have remained unknown up to now. Here, we have applied a cloning 
strategy based on the enrichment of proteins by affinity chromatography, 
peptide sequencing and heterologous expression of isolated candidate pro-
teins. The enrichment procedure followed the method of Myllyla et al. (31) 
using immobilized denatured collagen type I to capture the ColGalT. Homo-
genates of 10-day-old chicken embryos were used as source of ColGalT en-
zyme as applied previously (1, 23). To identify potential ColGalT enzymes 
among the proteins enriched by the affinity chromatography, we selected 
proteins sharing sequence homology with known glycosyltransferases. We 
also narrowed down on proteins containing ER-localization motifs consi-
dering the cellular localization of collagen glycosylation and on proteins 
containing N-glycosylation sites since it was shown that the ColGalT activity 
could by enriched by concanavalin-A lectin chromatography (29). 
One of the candidate proteins identified by tandem-MS peptide sequencing 
was the putative glycosyltransferase GLT25D2 (Fig. 1) (for further MS hits 
see supplementary Table A1). GLT25D2 is a type II transmembrane protein 
of 626 amino acids including four N-glycosylation sites and the ER-retention 
signal RDEL at the C-terminus. No enzymatic activity was attributed to 
GLT25D2 but database annotations pointed to sequence homology with 
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bacterial enzymes involved in LPS biosynthesis. Similar proteins to the 
chicken GLT25D2 could be deduced from all metazoan genomes. In the hu-
man genome, GLT25D2 was found to be strongly similar to two proteins, 
namely GLT25D1 and CEECAM1. The three proteins contained N-glycosyla-
tion sites and the ER retrieval signal RDEL at the C-terminus and shared 
above 50 % sequence identity (Fig. 2). 
ColGalT activity. The putative ColGalT activity of GLT25D1, GLT25D2 and 
CEECAM1 was assayed by expressing the three proteins as recombinant ba-
culovirus in Sf9 insect cells. Five types of collagen were tested as possible 
acceptor substrates. Because native collagen is readily glycosylated to vary-
ing extents, we also included deglycosylated collagen preparations in the 
assays. GLT25D1 and GLT25D2 showed a strong ColGalT activity on all 
deglycosylated collagen acceptors tested, whereas CEECAM1 did not show 
any activity (Table 1). As expected, the ColGalT activity of GLT25D1 and 
GLT25D2 was lower when using native collagen acceptors. Noteworthy, 
collagen type IV and collagen type V in the native form were hardly galacto-
sylated by GLT25D1 and GLT25D2, suggesting that most Hyl residues were 
already glycosylated. In addition to true collagens, GLT25D1 and GLT25D2, 
but not CEECAM1, were able to transfer Gal to the serum protein MBL (Fig. 
3), which contains four Hyl sites in its collagen domain, showing that Col-
GalT activity was not limited to large collagen acceptors. 
We also tested the ColGalT activity of the human LH3 enzyme, which had 
been reported to catalyze three reactions on collagen, namely the hydroxyla-
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tion of Lys, plus the β(1-O)galactosylation and α(1-2)glucosylation of Hyl (11, 
46). Surprisingly, we could not detect any significant ColGalT activity for 
LH3 under our assay conditions using native collagen type I as acceptor. 
However, as described previously (11, 46), we did measure a low collagen 
glucosyltransferase activity for LH3, whereas GLT25D1, GLT25D2 and CEE-
CAM1 failed to show any collagen glucosyltransferase activity (Fig. 4). The 
expression of CEECAM1 and the other recombinantly expressed enzymes 
was proven by tryptic digest and LC-MS analysis of Coomassie SDS-PAGE 
excised protein bands (Fig. 4C, LC-MS hits see supplementary figure A2). 
Reasons why we could not show the ColGalT activity and only a very low 
ColGlcT activity of LH3 could be the different collagen acceptor substrate 
preparations, or differences in the expression system. The apparent Km of 
GLT25D1 and GLT25D2 was determined for the native collagen type I ac-
ceptor substrate and for UDP-Gal, since these values had been reported pre-
viously for the semi-purified ColGalT activity (22). The Km of GLT25D1 and 
GLT25D2 for the collagen type I acceptor was 13.6 g/l and 9.8 g/l, respec-
tively, whereas Myllyla et al. reported a Km of 150 g/l for the partially puri-
fied chicken ColGalT enzyme. The Km values for UDP-Gal were 18.77 μM for 
GLT25D1 and 33.53 μM for GLT25D2. These values are comparable with 
Myllyla et al, who determined a Km for UDP-Gal of 30 μM for the partially 
purified chicken ColGalT (Fig. 5) (22).  
ColGalT reaction products. The products of the GLT25D1 and GLT25D2 me-
diated ColGalT reactions were further analyzed to confirm the transfer of Gal 
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to Hyl residues on collagen. The reaction products were hydrolyzed in 4 M 
NaOH to yield single amino acids. After derivatization with Fmoc and sepa-
ration by reverse phase HPLC, the amino acid profiles obtained from colla-
gen type I, collagen type II and from the GLT25D1-, GLT25D2-reacted colla-
gen acceptors were compared to a profile of authentic amino acid standards. 
The amount of GHyl and GGHyl was higher in collagen type II than in colla-
gen type I as measured by the ratio GHyl/Hyl and GGHyl/Hyl, respectively 
(Fig. 6). This finding was in agreement with the values reported in the lite-
rature (15). The analysis of additional types of collagen, such as collagen type 
IV and sponge collagen confirmed the variable extent of Hyl glycosylation 
across collagens (data not shown). The amino acid profiles obtained after 
GLT25D1 and GLT25D2 reactions in the presence of UDP-[14C]Gal were 
further analyzed by β-counting (Fig. 6, lower panel). The [14C]Gal signal co-
migrated with the GHyl standard.  
ColGalT gene expression. The expression of GLT25D1, GLT25D2 and CEE-
CAM1 in human tissues was determined by Northern Dot blotting using 
RNA arrays featuring 75 different human tissues and cell types and by a 
Northern Blot with mRNAs of 10 different organs (Fig. 7A). The GLT25D1 
gene was widely expressed in fetal and adult human tissues (Fig. 7B). By 
contrast, the GLT25D2 gene was expressed at much lower levels and only in 
the nervous system (Fig. 7B). The CEECAM1 gene, which could not be re-
lated to a ColGalT activity, showed a widespread expression across tissues, 
whereas CEECAM1 was highly expressed in secretory tissues like salivary 
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glands, pancreas and placenta and in the nervous system (Fig. 7B). Addition-
ally, the GLT25D1 and CEECAM1 genes, but not GLT25D2, were also ex-
pressed in various carcinoma cell lines (supplementary Fig. A1). This survey 
of ColGalT gene expression suggested that GLT25D1 represents the main 
source of ColGalT activity in the human organism, while GLT25D2 appears 
to be specialized to few cell types and possibly to few collagen acceptors. 
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Discussion 
The identification of the GLT25D1 and GLT25D2 ColGalT enzymes and of 
the similar, yet inactive, relative CEECAM1 protein raises the question of a 
possible restricted specificity towards collagen acceptor substrates. Previous 
work has shown that ColGalTs recognizes collagen peptides of at least 500-
600 Da and that Hyl alone is not a suitable acceptor (22, 30). The different 
activity levels of recombinant GLT25D1 and GLT25D2 enzymes towards the 
various types of collagen tested support the idea of a differential substrate 
recognition. The nature of the substrate recognition may be complex and 
may include glycosylated residues as part of the motifs recognized. In fact, 
GLT25D2 was more active towards native collagen type I and type II than 
towards the deglycosylated forms of these proteins (Table 1), which indicates 
that glycan chains somehow affected the recognition of the acceptor substrate 
by GLT25D2. Along the same line, the apparent inactivity of CEECAM1 may 
be due to stringent structural requirements regarding the recognition of 
collagen peptides. A similarly complex mechanism of substrate recognition 
has been described for core glycosyltransferases acting on mucin proteins. 
Some members of the polypeptide N-acetylgalactosaminyltransferase family 
recognize peptide acceptors including serine or threonine residues near resi-
dues that were previously glycosylated by other N-acetylgalactosaminyl-
transferases (3). ColGalT assays with synthetic peptides including Hyl and 
GHyl at various positions will certainly answer the question of the acceptor 
substrate recognition. 
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 Alternatively, it is possible that CEECAM1 represents a ColGalT acting on a 
limited set of substrates. The screening of additional proteins including col-
lagen domains like adiponectin, the acetylcholine esterase complex COLQ, 
and the complement protein C1q might confirm this eventuality. Finally, 
CEECAM1 may have lost any enzymatic activity over the course of evolu-
tion. In fact, CEECAM1 was first described as an adhesion protein (40), 
which might function as a carbohydrate-binding protein at the cell surface. 
However, the presence of the C-terminal RDEL motif would suggest that 
CEECAM1 is maintained in the ER. 
The lysylhydroxylase LH3 protein has been previously reported to possess 
three enzymatic activities, namely a lysylhydroxylase, a ColGalT and a colla-
gen glucosyltransferase activity (46). The glycosyltransferase activities attri-
buted to LH3 were very low, casting doubt on their biological significance 
(26). By comparison, the strong ColGalT activity described here for GLT25D1 
and GLT25D2 implies that these proteins indeed represent true ColGalT en-
zymes. The dual glycosyltransferase activity of LH3 certainly requires closer 
attention as it is expected that the catalysis of both β(1-O) and α(1-2) linkages 
would require distinct domains responsible for the retaining α(1-2) and in-
verting β(1-O) glycosyltransferase activities (25). 
The GLT25D1 and GLT25D2 genes are found on human chromosome 19p13 
and chromosome 1q25, respectively. The identification of these two ColGalT 
genes opens new ways to investigate the biological significance of collagen 
glycosylation. Knockdown experiments of the GLT25D1 and GLT25D2 or-
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tholog in C. elegans showed different phenotype aberrations like abnormal 
locomotion, slow growth and deformed mating organs (14, 35). Knockdown 
experiments of the LH ortholog showed embryonic lethality (20, 24). These 
findings in C. elegans point out the importance of correct collagen glycosyla-
tion in development. In humans, ColGalTs are involved in the pathogenesis 
of connective tissue disorders linked to chromosomes 19p13 and 1q25, such 
as psoriasis (18) and epidermolysis bullosa (8, 17). The identification of these 
ColGalTs enables now further investigations in the relationship between 
these enzymes and connective tissue disorders.  
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Appendix  
Supplementary Table A1: MS mascot search result of ColGalT identification 
Protein Hits Description 
UPI0000E23134 Cluster: PREDICTED: similar to keratin 1; n=1; Pan troglo-dytes|Rep: PREDICTED: similar to keratin 1 - Pan troglodytes 
UPI0000E2470B 
Cluster: PREDICTED: similar to Keratin, type I cytoskeletal 14 (Cy-
tokeratin-14) (CK-14) (Keratin-14) (K14); n=1; Pan troglodytes|Rep: 
PREDICTED: similar to Keratin, type I cytoskeletal 14 (Cytokeratin-
14) (CK-14) (Keratin-14) (K14) - Pan troglodytes 
ZZ_FGCZCont0112 sp|ALBU_BOVIN|  
ZZ_FGCZCont0184 gi|229552|prf|| 754920A albumin [Bos primigenius taurus]  
ZZ_FGCZCont0156 gi|136425|sp|P00760| TRYP_BOVIN TRYPSINOGEN.  
UPI0000E24772 Cluster: PREDICTED: keratin 25D isoform 4; n=1; Pan troglo-dytes|Rep: PREDICTED: keratin 25D isoform 4 - Pan troglodytes 
A5A6P6 Cluster: Keratin 2A; n=1; Pan troglodytes verus|Rep: Keratin 2A - Pan troglodytes verus 
UPI000155E6FC Cluster: PREDICTED: similar to Keratin 6A; n=1; Equus cabal-lus|Rep: PREDICTED: similar to Keratin 6A - Equus caballus 
UPI0000E203B1 Cluster: PREDICTED: albumin; n=1; Pan troglodytes|Rep: PRE-DICTED: albumin - Pan troglodytes 
UPI00003690AA Cluster: PREDICTED: lipocalin 1; n=2; Homo/Pan/Gorilla 
group|Rep: PREDICTED: lipocalin 1 - Pan troglodytes 
UPI0000EB2272 
Cluster: Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) 
(Keratin-10) (K10) (Epithelial keratin-10).; n=1; Canis lupus famil-
iaris|Rep: Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) 
(Keratin-10) (K10) (Epithelial keratin-10). - Ca 
UPI0000ECB29B 
Cluster: glycosyltransferase 25 domain containing 2; n=1; Gallus 
gallus|Rep: glycosyltransferase 25 domain containing 2 - Gallus 
gallus 
A5PMF6 
Cluster: Glycosyltransferase 25 family member 1 precursor; n=1; 
Danio rerio|Rep: Glycosyltransferase 25 family member 1 precursor 
- Danio rerio (Zebrafish) (Brachydanio rerio) 
UPI000069E8D4 
Cluster: glycosyltransferase 25 domain containing 2; n=1; Xenopus 
tropicalis|Rep: glycosyltransferase 25 domain containing 2 - 
Xenopus tropicalis 
UPI0000D9CC7A Cluster: PREDICTED: keratin 5 isoform 8; n=1; Macaca mu-
latta|Rep: PREDICTED: keratin 5 isoform 8 - Macaca mulatta 
Q0MRP5 Cluster: Lysozyme C; n=2; Bovidae|Rep: Lysozyme C - Bos indicus 
x Bos taurus (hybrid cattle) 
P08515 
Cluster: Glutathione S-transferase class-mu 26 kDa isozyme; n=2; 
Schistosoma japonicum|Rep: Glutathione S-transferase class-mu 
26 kDa isozyme - Schistosoma japonicum (Blood fluke) 
Q5XKQ4 
Cluster: Alpha-2-glycoprotein 1, zinc-binding; n=1; Homo 
sapiens|Rep: Alpha-2-glycoprotein 1, zinc-binding - Homo sapiens 
(Human) 
A1SFN4 
Cluster: Putative uncharacterized protein; n=1; Nocardioides sp. 
JS614|Rep: Putative uncharacterized protein - Nocardioides sp. 
(strain BAA-499 / JS614) 
A0A9F3 Cluster: Prolactin-induced protein; n=1; Homo sapiens|Rep: 
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Prolactin-induced protein - Homo sapiens (Human) 
UPI0000DC1FE0 Cluster: RGD1311906 protein; n=1; Rattus norvegicus|Rep: 
RGD1311906 protein - Rattus norvegicus 
Q5BZZ6 Cluster: SJCHGC01457 protein; n=1; Schistosoma japonicum|Rep: 
SJCHGC01457 protein - Schistosoma japonicum (Blood fluke) 
UPI0000F338C8 
Cluster: Keratin, type II cytoskeletal 5 (Cytokeratin-5) (CK-5) (Kera-
tin-5) (K5).; n=1; Bos taurus|Rep: Keratin, type II cytoskeletal 5 
(Cytokeratin-5) (CK-5) (Keratin-5) (K5). - Bos Taurus 
UPI0000E1FC56 
Cluster: PREDICTED: lactotransferrin isoform 5; n=1; Pan troglo-
dytes|Rep: PREDICTED: lactotransferrin isoform 5 - Pan troglo-
dytes 
A6UD50 
Cluster: Sarcosine oxidase, alpha subunit family; n=1; Sinorhizo-
bium medicae WSM419|Rep: Sarcosine oxidase, alpha subunit 
family - Sinorhizobium medicae (strain WSM419) (Ensifer medicae) 
A3TU89 
Cluster: Ferric anguibactin transport system permease protein fatc; 
n=1; Oceanicola batsensis HTCC2597|Rep: Ferric anguibactin 
transport system permease protein fatc - Oceanicola batsensis 
HTCC2597 
Q55FK8 
Cluster: Putative uncharacterized protein; n=1; Dictyostelium dis-
coideum|Rep: Putative uncharacterized protein - Dictyostelium dis-
coideum (Slime mold) 
Q0YHZ7 
Cluster: Geobacter sulfurreducens, CxxxxCH...CXXCH motif; n=1; 
Geobacter sp. FRC-32|Rep: Geobacter sulfurreducens, 
CxxxxCH...CXXCH motif - Geobacter sp. FRC-32 
A0TMF4 
Cluster: Putative uncharacterized protein; n=1; Burkholderia ambi-
faria MC40-6|Rep: Putative uncharacterized protein - Burkholderia 
ambifaria MC40-6 
 
 
Supplementary Table A2: HPLC gradient 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
Solvent C 
[%] 
0.0 75 0 25
74.2 64 0 36 
78.7 64 0 36 
78.9 0 65 35 
104.0 0 65 35 
129.3 0 25 75 
135.3 0 25 75 
153.1 75 0 25 
188.9 75 0 25 
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Supplementary Figure A1: Tissue Northern blot. The mRNA expression patterns of 
GLT25D1, GLT25D2 and CEECAM1 were analyzed in 75 human tissues and cell 
lines. The 39 tissues and cell lines not presented in Fig. 7 are shown here. 
 
Supplementary Figure A2: MS mascot search result. Proteins expressed in 
Sf9 cells using the baculovirus system were separated on a SDS-PAGE gel. 
Protein bands were cut from the gel, digested with trypsin and analyzed by 
LC-MS. The MS mascot search result of recombinantly expressed GLT25D1, 
GLT25D2, CEECAM1 and LH3 is shown. 
 
 
Supplementary Figure A1 
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Supplementary Figure A2 
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Table 1. ColGalT activity measured in Sf9 cell lysates. Values represent the 
average ± S.D. of 4 assays. 
Collagen TFMS a Sf9 b GLT25D1 GLT25D2 CEECAM1 
  (pmol.min-1.mg prot-1) 
no acceptor  1.5 ± 0.6 1.9 ± 0.7 0.9 ± 0.4 0.5 ± 0.1 
- 10.5 ± 1.8 43.7 ± 12.0 57.2 ± 8.5 8.7 ± 2.0 Type I 
+ 5.0 ± 3.0 61.4 ± 18.2 18.0 ± 5.4 2.7 ± 1.9 
- 6.5 ± 0.8 36.6 ± 3.7 35.1 ± 3.8 3.3 ± 1.3 Type II 
+ 3.4 ± 0.8 67.0 ± 16.5 22.1 ± 8.8 2.8 ± 0.8 
- 2.9 ± 0.9 31.7 ± 5.8 25.2 ± 6.8 1.8 ± 0.8 Type III 
+ 11.0 ± 3.6 244.7 ± 25.7 102.1 ± 17.6 6.5 ± 1.7 
- 1.7 ± 1.4 3.6 ± 2.2 3.6 ± 0.9 1.9 ± 0.7 Type IV 
+ 12.9 ± 4.6 433.2 ± 49.6 164.2 ± 43.3 8.4 ± 2.4 
- 2.3 ± 0.7 2.7 ± 0.3 2.3 ± 0.4 0.7 ± 0.1 Type V 
+ 2.7 ± 1.6 18.6 ± 3.6 4.7 ± 1.5 2.0 ± 1.1 
 
a TFMS-mediated deglycosylation 
b Sf9 cells infected with an empty baculovirus 
 
 
Results 
75 
Figure Legends 
Fig. 1: ColGalT identification by mass spectrometry. Proteins isolated by af-
finity chromatography were analyzed by LC-MS. (A) Peptide fragment 
spectra of two peptides identifying GLT25D2, (B) protein sequence of the 
Gallus gallus GLT25D2. The two identifying peptides are shaded in grey, the 
four potential N-glycosylation sites are underlined and the ER retrieval sig-
nal is shown in bold. 
 
Fig. 2: Protein alignment. The three putative human ColGalT enzymes share 
a high degree of sequence identity (63 % between GLT25D1 and GLT25D2, 
50% between GLT25D2 and CEECAM1, 55 % between GLT25D1 and CEE-
CAM1). The proteins include the C-terminal RDEL ER retrieval motif. Black 
squares represent amino acids identical or similar in all 3 proteins; grey 
squares represent amino acids identical or similar in 2 of the proteins. 
 
Fig. 3: ColGalT activity towards MBL. ColGalT activity assay was performed 
as described in the Experimental procedures section. Bars indicate the means of 
four assays. Error bars indicate the SD. 
 
Fig. 4: Time course of baculovirus mediated protein expression in Sf9 cells. 
(A) ColGalT activity and (B) collagen glucosyltransferase activity measured 
in cells expressing GLT25D1 (▲), GLT25D2 (), CEECAM1 (), LH3 (z). 
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Bovine collagen type I was used as acceptor substrate. The activity measured 
in Sf9 infected with an empty baculovirus is shown in both panels with filled 
squares (). Bars indicate the means of four assays. Error bars indicate the 
SD. (C) Coomassie SDS-PAGE of recombinantly expressed proteins. Arrows 
indicate the protein bands analyzed by LH-MS. 
 
Fig. 5: Michaelis-Menten kinetics. Determination of the apparent Km of 
GLT25D1 and GLT25D2 for the collagen type I acceptor substrate. (A) Line-
weaver Burk blot for GLT25D1 on collagen, with the calculated Michaelis-
Menten constant of 13.6 g/l. (C) Lineweaver Burk blot for GLT25D2 on colla-
gen with the calculated Michaelis-Menten constant of 9.8 g/l. (B) Lineweaver 
Burk blot for GLT25D1 on UDP-Gal with the calculated Michaelis-Menten 
constant of 18.77 μM . (D) Lineweaver Burk blot for GLT25D2 on UDP-Gal 
with the calculated Michaelis-Menten constant of 33.53 μM. 
 
Fig. 6: Product identification by RP-HPLC. The first panel represents an 
amino acid standard containing the standards for G-Hyl and GG-Hyl. The 
second and the third panels show the amino acid profiles of bovine collagen 
type I and type II hydrolysates, respectively. The lower two panels show the 
radioactive trace obtained after reaction of collagen type I with GLT25D1 and 
GLT25D2. [3H]Val and [14C]Tyr were used as internal amino acid standards. 
Amino acids are marked in single-letter code. Hyp, hydroxyproline.  
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Fig. 7: Tissue Northern blot. The mRNA expression patterns of GLT25D1, 
GLT25D2 and CEECAM1 were analyzed in 10 human organs (A) (lane 1: 
brain, 2: placenta, 3: skeletal muscle, 4: heart, 5: kidney, 6: pancreas, 7: liver, 
8: lung, 9: spleen, 10: colon) as well as in 75 human tissues and cell lines, 
whereas a representative collection of 36 tissues is shown in panel (B) (see 
also supplementary Fig. A1). PBL, peripheral blood leukocytes. 
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Figure 1 
 
 
XGSIADHWSEKKSMCISNGRKLILIASRTVSILTIVTHRA    1
SYPGASGWLPLEQMTWHQLPSAVQGCSAILQYTAVGEGPR   41
ILQPSEHGQEGKGSLLQLQQPPAFALFCTLETLIMKYLPL   81
FANGGGWVATDHNADNTTAILREWLKNVQNLYHDVEWRPM  121
EDPQSYPEEMGPKHWPSSRFTHVMKLRQAALRAAREKWSD  161
YVLFLDTDNLLTNPETLNLLIAENKTLVAPMLESRFLYSN  201
FWCGITPQAGGWGYYKRTLDYPLIREWKRTGCFAVPMIHS  241
TFLIDLRKEASTKLMFYPPHQDYTWSFDDIMVFAFSSRQA  281
GIQMFICNREHYGFLPMPLKSHQTLQEETENFVHTLIEAM  321
SKWLCPAVLEPPVSICRHVQLYQSSVYLQVMVGISALFQS  361
IVLPLSPLSMSLFLRSALTRWDLMKALNTSQLKALSIDML  401
PGYRDPYSSRPLTRGEIGCFLSHYYIWKEVVNRGLEKTLV  441
IEDDVRFEHQFKRKLMKLMDDIEQAQLDWELIYIGRKRMQ  481
VQQPEKAVPNVMNLVEADYSYWTLGYAISFQGAQKLIGAE  521
PFSKMLPVDEFLPVMYNKHPVAKYMEYYESRDLKAFSAEP  561
LLVYPTHYTGQPGYLSDTETSTIWDNETVSTDWDRTHSWK  601
SRQQGQIHSEAQNKDALPPQSSLNAPSSRDEL 641
B
A
 
Results 
79 
Figure 2 
 
 
 
                            20                  40                  60                  80                 100            
GLT25D1 : MAAAPRAGRRRGQPLLALLLLLLAPLP-PGAPPGADAYFPEERWSPESPLQAPRVLIALLARNAAHALPTTLGALERLRHPRERTALWVATDHNMDNTSTVLREW : 104 
GLT25D2 : MAARPAATLAWSLLLLSSALLREGCRARFVAERDSEDDGEEPVVFPESPLQSPTVLVAVLARNAAHTLPHFLGCLERLDYPKSRMAIWAATDHNVDNTTEIFREW : 105 
CEECAM1 : MRAARAAPLLQLLLLLGPWLEAAG--------------------VAESPL--PAVVLAILARNAEHSLPHYLGALERLDYPRARMALWCATDHNVDNTTEMLQEW :  83 
                                                                                                                          
                      120                 140                 160                 180                 200                 
GLT25D1 : LVAVKSLYHSVEWRPAEEPRSYPDEEGPKHWSDSRYEHVMKLRQAALKSARDMWADYILFVDADNLILNPDTLSLLIAENKTVVAPMLDSRAAYSNFWCGMTSQG : 209 
GLT25D2 : LKNVQRLYHYVEWRPMDEPESYPDEIGPKHWPTSRFAHVMKLRQAALRTAREKWSDYILFIDVDNFLTNPQTLNLLIAENKTIVAPMLESRGLYSNFWCGITPKG : 210 
CEECAM1 : LAAVGDDYAAVVWRPEGEPRFYPDEEGPKHWTKERHQFLMELKQEALTFARNWGADYILFADTDNILTNNQTLRLLMGQGLPVVAPMLDSQTYYSNFWCGITPQG : 188 
                                                                                                                          
                 220                 240                 260                 280                 300                      
GLT25D1 : YYKRTPAYIPIRKRDRRGCFAVPMVHSTFLIDLRKAASRNLAFYPPHPDYTWSFDDIIVFAFSCKQAEVQMYVCNKEEYGFLPVPLRAHSTLQDEAESFMHVQLE : 314 
GLT25D2 : FYKRTPDYVQIREWKRTGCFPVPMVHSTFLIDLRKEASDKLTFYPPHQDYTWTFDDIIVFAFSSRQAGIQMYLCNREHYGYLPIPLKPHQTLQEDIENLIHVQIE : 315 
CEECAM1 : YYRRTAEYFPTKNRQRRGCFRVPMVHSTFLASLRAEGADQLAFYPPHPNYTWPFDDIIVFAYACQAAGVSVHVCNEHRYGYMNVPVKSHQGLEDERVNFIHLILE : 293 
                                                                                                                          
            320                 340                 360                 380                 400                 420       
GLT25D1 : VMVKHPPAEPSRFISAPTKTPDKMGFDEVFMINLRRRQDRRERMLRALQAQEIECRLVEAVDGKAMNTSQVEALGIQMLPGYRDPYHGRPLTKGELGCFLSHYNI : 419 
GLT25D2 : AMIDRPPMEPSQYVSVVPKYPDKMGFDEIFMINLKRRKDRRDRMLRTLYEQEIEVKIVEAVDGKALNTSQLKALNIEMLPGYRDPYSSRPLTRGEIGCFLSHYSV : 420 
CEECAM1 : ALVDGPRMQASAHVTRPSKRPSKIGFDEVFVISLARRPDRRERMLASLWEMEISGRVVDAVDGWMLNSSAIRNLGVDLLPGYQDPYSGRTLTKGEVGCFLSHYSI : 398 
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GLT25D1 : WKEVVDRGLQKSLVFEDDLRFEIFFKRRLMNLMRDVEREGLDWDLIYVGRKRMQVEHPEKAVPRVRNLVEADYSYWTLAYVISLQGARKLLAAEPLSKMLPVDEF : 524 
GLT25D2 : WKEVIDRELEKTLVIEDDVRFEHQFKKKLMKLMDNIDQAQLDWELIYIGRKRMQVKEPEKAVPNVANLVEADYSYWTLGYVISLEGAQKLVGANPFGKMLPVDEF : 525 
CEECAM1 : WEEVVARGLARVLVFEDDVRFESNFRGRLERLMEDVEAEKLSWDLIYLGRKQVNPEK-ETAVEGLPGLVVAGYSYWTLAYALRLAGARKLLASQPLRRMLPVDEF : 502 
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GLT25D1 : LPVMFDKHPVSEYKAHFSLRNLHAFSVEPLLIYPTHYTGDDGYVSDTETSVVWNNEHVKTDWDRAKSQKMREQQALSREAKNSDVLQSP--LDSA-ARDEL : 622 
GLT25D2 : LPVMYNKHPVAEYKEYYESRDLKAFSAEPLLIYPTHYTGQPGYLSDTETSTIWDNETVATDWDRTHAWKSRKQSRIYSNAKNTEALPPPTSLDTVPSRDEL : 626 
CEECAM1 : LPIMFDQHPNEQYKAHFWPRDLVAFSAQPLLAAPTHYAGDAEWLSDTETSSPWDDDSGR-LISWSGSQKTLRSPRLDLTGSSGHSLQPQ-------PRDEL : 595 
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Figure 3 
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Figure 5 
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Figure 6 
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Figure 7 
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2.1.2 Further Characterization of the Human ColGalTs 
2.1.2.1 Synthetic Peptides as Acceptor Substrate 
In chapter 2.1.1 we described that GLT25D1 and GLT25D2 are able to gly-
cosylate different acceptor substrates namely collagen type I-V and the non-
collagenous protein MBL. In a further step, we have expanded the study of 
the ColGalT enzymes on additional acceptor substrates. We have investi-
gated synthetic peptides representing sequences containing Hyl, as found in 
human ADIPOQ, in the α1-chain of human collagen type II (Col2A1) and in 
the mimivirus collagen L71. These peptides were kindly provided by 
NeoMPS, PolyPeptide Laboratories Group, France. As shown in the first part 
of the results section (Chapter 2.1), the GLT25D1 enzyme was able to glyco-
sylate the non-collagenous protein MBL. Using the synthetic peptide accep-
tors, we could demonstrate that GLT25D1 is also capable of glycosylating the 
ADIPOQ peptide (Figure 14). Furthermore, the GLT25D1 could glycosylate 
L71, a collagen of the mimivirus. These results show that the acceptor speci-
ficity of the human GLT25D1 enzyme is not restricted to human collagens. 
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Figure 14: Enzymatic Activity Assay using Synthetic Peptides. Synthetic peptides repre-
senting human adiponectin (ADIPOQ), mimiviral L71 and human Col2A1 were used as sub-
strate in the enzymatic activity assay using GLT25D1 as galactosyltransferase. Peptide se-
quences: ADIPOQ: GDPGLIGP-Hyl-LGDIGETGVP, L71: GDVGD-Hyl-GDVGD-Hyl-GDVGD-
Hyl-GD, COL2A1: GPTGVTGP-Hyl-GARGAQGP. Error bars represent standard deviations 
of n=4. 
 
2.1.3 ColGalT and ColGlcT in Diseases 
As reviewed in chapter 1.2.5 many mutations in collagen processing en-
zymes can lead to a series of diseases. Having in mind that glycans play an 
important role in many proteins, our hypothesis was that the carbohydrates of 
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collagen may also play an important role in the function of collagen. In order 
to investigate this hypothesis, we have been looking for impaired collagen 
glycosylation in patients showing abnormalities in skin stability. 
2.1.3.1 Ehlers-Danlos Syndrome Patients 
Since EDS VIb patients show a normal LH activity but share the same phe-
notype as EDS VIa, we hypothesized that mutations in the collagen glycosyl-
transferases resulting in an impaired modification of the hydroxylysine could 
be involved in this disease. As mutations in the collagen glycosyltransferases 
could be involved in this disease, fibroblasts of EDS VIb patients were inves-
tigated (fibroblasts were kindly provided by B. Steinmann, University Chil-
dren’s Hospital Zurich, Switzerland and L. Bonafé, Centre Hospitalier Univer-
sitaire Vaudois, Lausanne, Switzerland). Cell lysates of these patient fibro-
blasts were used as a source for the collagen glycosyltransferases and as-
sayed on the acceptor collagen type I. Figure 15 shows the enzymatic activity 
assays using the donor substrates UDP-Gal (panel A) and UDP-Glc (panel 
B).  
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Figure 15: Enzymatic Activity in EDS VIb patients. Six EDS VIb patient fibroblasts were 
assayed using either UDP-Gal (A) or UDP-Glc (B) as substrate and compared with the two 
healthy control fibroblasts. Error bars represent standard deviations of n=2-5. 
 
Comparing the enzymatic activities of healthy control fibroblast with the 
enzymatic activities of the six different EDS VIb patients, no significant re-
duction of one of the collagen glycosyltransferases was detected as would be 
expected, if one of these enzymes would be mutated. This indicates that 
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probably none of the collagen glycosyltransferases are involved in the EDS 
VIb disease.  
2.1.3.2 Brittle Cornea Syndrome Patients 
Since BCS patients show a similar phenotype as EDS VI patients and since 
the cause of the disease is still unknown, fibroblasts of BCS patients were 
also tested for an altered ColGalT activity (fibroblasts were kindly provided by 
B. Steinmann, University Children’s Hospital Zurich, Switzerland). Figure 16 
shows the ColGalT (A) and ColGlcT (B) enzymatic activities measured in 
BCS patient fibroblasts. Although in patient number 1 a reduction of activity 
was visible, no loss of ColGalT or ColGlcT activity could be detected as it 
would be expected if one of the glycosyltransferase activities would be defi-
cient.  
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Figure 16: Enzymatic Activity of BCS patients. Six different BCS patient fibroblasts were 
assayed using either UDP-Gal (A) or UDP-Glc (B) as substrate and compared with the two 
healthy control fibroblasts. Error bars represent standard deviations of n=3-4. 
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2.2 Characterization of a Viral ColGlcT 
2.2.1 Manuscript 2 
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Abstract 
The Acanthamoeba polyphaga mimivirus is the largest virus described to date. 
Within its 1.2 Mbp linear DNA genome, eight open reading frames with 
collagen triple helix motifs are encoded. These collagenous proteins are 
probably involved in the formation of the fibrils surrounding the icosahedral 
capsid of mimivirus. Animal collagens are hydroxylated and subsequently 
glycosylated on hydroxylysine. Mimivirus contains genes in its genome, 
which show similarities to animal lysyl hydroxylase and prolyl hydroxylase 
genes, which suggests that mimiviral collagens may be also post-translation-
ally modified. Furthermore, genes encoding potential collagen glycosyltrans-
ferases could be retrieved from the mimivirus genome. In the present study, 
we have cloned and characterized the mimiviral L230 gene. We could show 
that L230 encodes a collagen glucosyltransferase enzyme, which transfers 
glucose on hydroxylysines found in collagen motifs. This work represents 
the first report on a virally encoded collagen glycosyltransferase. 
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Introduction 
The Acanthamoeba polyphaga mimivirus (MIMIV) is the largest virus 
characterized to date. MIMIV belongs to the Mimiviridiae family of nucleo-
cytoplasmic large DNA viruses. The viral core contains a 1.2 Mbp linear 
dsDNA genome coding for a total of 911 predicted proteins, which are in-
volved in amino acid transport and metabolism, translation and post-trans-
lational modifications (12, 19). The virus has a icosahedral capsid surrounded 
by fibrils with a total diameter of 650 nm. The 120 nm long external fibrils are 
unique for MIMIV (19). Raoult (12) and Xiao (23) reported that MIMIV con-
tains eight open reading frames with collagen motifs in its genome, which 
are most probably found in the fibrils of the virus capsid. The predominant 
occurrence of lysine in the viral collagen motifs enables the formation of hy-
droxylysine (Hyl) and glycosylated Hyl. The positive Gram staining of 
MIMIV particles suggests the presence of carbohydrates on the surface of the 
virus, thereby supporting the notion that collagen might be glycosylated (12). 
The process of glycosylation of animal collagens is well known (4). Lysines 
within the collagen triple helical domain are hydroxylated and the resulting 
Hyl serve then as acceptors for either the monosaccharide galactose or the 
disaccharide glucosylgalactose. The MIMIV genome encodes putative en-
zymes such as lysyl hydroxylase and prolyl hydroxylase, which are involved 
in the post-translational modifications of collagen (12). This fact suggests that 
mimiviral collagen are post-translationally hydroxylated and might be glyco-
sylated by virus-encoded enzymes. The present study focuses on the charac-
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terization of a MIMIV gene encoding a putative enzyme combining lysyl hy-
droxylase and collagen glycosyltransferase domains. Collagen or collagen 
like proteins are not only seen in higher eukaryotes but also in bacteria (13, 
14, 24), sponges (7), fungi (2) and even the Chlorella virus encodes in its ge-
nome a collagen gene (25). Post-translational modifications of collagen, 
including collagen glycosylation are conserved processes. Glycosylated col-
lagens are not only present in higher animals but are also found in sponges 
(7). 
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Materials and Methods 
Cloning and protein expression. MIMIV genomic DNA was isolated ac-
cording to Raoult et al (12). L230 was cloned from viral genomic DNA using 
the primers 5'- GACCCATGGGATCCATTAGTAGAACTTATGTAAT-3' and 
5'- GTCACTAGTTTAATTAACAAAAGACACTAAAATAT-3' (Microsynth). 
The PCR product was cloned into the baculovirus transfer vector pFastBacI 
(Invitrogen) by the NcoI and SpeI restriction sites. The C-terminal deletion 
construct of L230 (L230 ΔC-term) was amplified with the primers 5'-GTGAC-
TAGGCCTTATTCATACCGTCCCACCATC-3' and 5'-CTAGCTCGAGGCA-
TGAGAGGACCTACAAAA-3' and cloned in pFastBacI with the restriction 
sites StuI and XhoI. The N-terminal deletion construct of L230 (L230 ΔN-
term) was amplified with the primers 5'-AAAAAGCAGGCTTAATGATTA-
GTAGAACTTATG-3' and 5'-AGAAAGCTGGGTATCATTAATTAACAAA-
AGACAC-3' in the baculovirus transfer vector pDEST8. The human lysyl 
hydroxylase 1 (LH1) cDNA was purchased from the RZPD repository (Berlin, 
Germany) and cloned by PCR with the primers 5'-AAAAAGCAGG-
CTTAATGCGGCCCCTGCTGCTA-3' and 5'-AGAAAGCTGGGTATTAGGG-
ATCGACGAAGGA-3' into the vector pDEST8. Recombinant baculoviruses 
were produced in S. frugiperda Sf9 cells as described previously (6). 
 
Preparation of collagen acceptors. Bovine achilles collagen type I (Sigma-Al-
drich) was incubated in 0.1 N NaOH for 1 h at 37 °C and brought to pH 6.8 
with acetic acid (16). Synthetic peptides including Hyl were designed to 
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represent sequences derived from human adiponectin ADIPOQ 
(GDPGLIGP-Hyl-GDIGETGVP), the MIMIV L71 protein (GDVGD-Hyl-
GDVGD-Hyl-GDVGD-Hyl-G) and human collagen type II (COL2A1) 
(GPTGVTGP-Hyl-KGARGAQGP). The peptides were kindly provided by 
NeoMPS, PolyPeptide Laboratories Group, France and dissolved in H2O. 
 
Collagen glycosyltransferase assay. Sf9 cells infected with recombinant 
baculoviruses were harvested three days post infection and lyzed in 1 % 
Triton-X100 for 10 min on ice. Postnuclear supernatants were used as en-
zyme source. The collagen acceptors were heat denatured for 10 min at 60 °C 
and subsequently cooled down to 0 °C. The enzymatic activity assays were 
performed with 10 μl of the Sf9 postnuclear supernatant in a volume of 
100 μl containing 500 μg collagen or 50 μg synthetic peptide acceptor, 60 μM 
UDP-Galactose (UDP-Gal) or UDP-Glucose (UDP-Glc), 50,000 cpm UDP-
[14C]Gal or UDP-[14C]Glc (GE Healthcare), 10 mM MnCl2, 20 mM NaCl, 
50 mM MOPS pH 7.4, 1 mM DTT. After an incubation time of 3 h at 37 °C, 
the reaction was stopped by the addition of 500 μl of ice cold 5 % TCA / 5 % 
phosphotungstic acid.  
 
Collagen lysyl hydroxylase assay. The lysyl hydroxylase assay was per-
formed according to Kivirikko et al (8) with radioactive 2-oxo[1-14C]glutarate 
(PerkinElmer) and 10 μg synthetic collagen peptide acceptors with the amino 
acid sequence (GIK)4 (3, 22) and (GDK)4 (Thermo Scientific). The reaction 
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was incubated for 45 min at 37 °C and the production of [14C]O2 was deter-
mined in a β-counter (Tri-Carb 2900TR, Packard). 
 
Amino acid analysis. The products of collagen glucosyltransferase (ColGlcT) 
assays were hydrolyzed in 4 M NaOH for 72 h at 105 °C. The resulting single 
amino acids were derivatized with Fmoc according to Bank et al. (1). Separa-
tion of Fmoc labelled amino acids was performed on a RP-HPLC (LaChrom 
Hitachi, Merck) using an ODS Hypersil column, 150 x 3 mm, 3 μm particle 
size (Thermo Electron Corporation) at 40 °C. The amino acids were separated 
at a flow rate of 0.2 ml/min using a gradient elution (Table A1) with the sol-
vents 0.5 M citric acid, 5 mM (CH3)4NCl, pH 2.85 (A); 80 % of 20 mM sodium 
acetate trihydrate, 5 mM (CH3)4NCl, pH 4.5, 20 % of methanol (B); 100 % of 
ACN (C). Radiolabelled [3H]Val and [14C]Tyr (Moravek Biochemicals and 
Radiochemicals, USA) were used as internal standard. The galactosylated 
Hyl (GHyl) and galactosyl-glucosylated Hyl (GGHyl) standards were kindly 
provided by Ruggero Tenni (University of Pavia) (21). The fractions collected 
from the HPLC runs were counted in a β-counter (Tri-Carb 2900TR, Pack-
ard). 
Northern blotting. A. polyphaga cells were infected with MIMIV for different 
time periods. 2.5 μg RNA of mock, 4, 8, 16 and 24 hours post infection (hpi) 
were separated on a 1 % formaldehyde-agarose gel and transferred on a 
nylon membrane (Hibond-N, GE Healthcare). The L230, R699 and R241 
probes were amplified by PCR using mimiviral genomic DNA with the 
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primers 5'-ACTGGGCTTGCGCATATGTC-3', 5'-GGTTGGTGCACATGGA-
ATAG-3' giving a product of 515 bp, 5'-TGAAGCTGGAGGTGGACAA-3', 5'-
GAGCCGACAGATCATTAG-3' giving a product of 641 bp and 5'-AGGTG-
GTGGTGGTGGTATTG-3', 5'-TGAGCGGGAATAGTTGTGGG-3' giving a 
product of 321 bp, respectively. DNA probes were labelled with α[32P]dCTP 
(Hartmann Analytic, Germany) by random priming (Stratagene). Membranes 
were incubated for 2 h at 80 °C and prehybridized for 1 h at 64 °C with 
QuikHyb® hybridization solution (Stratagene) containing 100 μg/ml ultra 
pure herring sperm DNA (Invitrogen). Hybridization was performed over-
night at 64 °C using 5 x 105 cpm per ml hybridization solution of each la-
belled probe. Membranes were washed in 0.1 x SSC, 0.1 % SDS up to 60 °C 
and exposed on BioMax XAR film (Kodak) for 24 h at RT.  
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Results 
ColGlcT identification. Much is known about eukaryotic glycosylation, but 
only little about virus encoded glycosyltransferases (5, 10, 18). As MIMIV 
stains positive in the Gram staining (12) and as we suppose that this could 
arise from the glycosylated collagenous fibrils on the virus capsid surface, we 
have searched for mimiviral encoded glycosyltransferases. The human colla-
gen galactosyltransferases (ColGalTs) GLT25D1 and GLT25D2 as well as the 
non-active homologue CEECAM1 (15) were blasted against proteins of other 
species and aligned using the ClustalW algorithm (Fig. 1). The ColGalTs are 
conserved within the eukaryotes, but there are also orthologous proteins in a 
variety of bacteria and even in MIMIV. To identify the mimiviral collagen 
glycosyltransferases, the MIMIV genome was blasted against the human 
GLT25D1 and GLT25D2 ColGalTs. In a blast search, the MIMIV proteins 
R699, R655, R654 and L230 were found as potential mimiviral collagen glyco-
syltransferases, since these viral proteins contained sequence motifs similar 
to regions of the human ColGalT enzymes. The putative MIMIV collagen 
glycosyltransferase L230 showed not only sequence homology to the human 
ColGalTs GLT25D1 and GLT25D2 (15) in its N-terminal region, but also 
showed a homology to the human LH1, LH2 and LH3 in its C-terminal do-
main (Fig. 2). This sequence homology suggests that L230 may possess two 
activities. It may act as a viral collagen lysyl hydroxylase and also as a viral 
collagen glycosyltransferase. 
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ColGlcT activity. The putative collagen glycosyltransferase activity of L230 
was assayed using the baculovirus protein expressing system in Sf9 insect 
cells. Recombinant L230 was tested on bovine collagen type I acceptor for 
collagen glucosyl- and galactosyltransferase activity. As depicted in figure 3, 
L230 showed a ColGlcT activity, whereas the enzyme was unable to use 
UDP-Gal as substrate in spite of its sequence homology to the human Col-
GalT enzymes.  
Beside bovine collagen type I, three synthetic peptides were tested as accep-
tor substrates, a peptide derived from the mimiviral collagen L71, from the 
human Col2A1 and from the collagen domain of human adiponectin (ADI-
POQ). The L230 protein was not only able to glucosylate the mimiviral colla-
gen but also the human Col2A1 and the human ADIPOQ peptides (Fig. 4).  
 
ColGlcT product analysis. The product of the enzymatic activity assays us-
ing L230 as ColGlcT was further analyzed by reverse phase HPLC to confirm 
the transfer of Glc to Hyl. The product of the reaction between L230 and the 
collagen type I acceptor was hydrolyzed in 4 M NaOH and the resulting 
single amino acids were labelled with Fmoc. The amino acid profile of the 
reaction product of L230 with UDP-[14C]Glc was further analyzed by β-
counting. The profile of radioactive counts (Fig. 5, lower panel) was com-
pared with a 17 amino acid standard containing the standard GHyl and 
GGHyl and with collagen type II. In animal collagen, Glc is transferred on 
GHyl. As we could measure a ColGlcT activity for L230, it was expected 
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from the product analysis that the radioactive counts co-migrate with the 
GGHyl standard. Surprisingly, [14C]Glc, which was transferred to collagen 
by L230, co-migrated with GHyl and not GGHyl. Therefore, L230 was shown 
to encode a ColGlcT that utilizes Hyl as acceptor. Mimiviral collagen glyco-
sylation seems to be different than the mammalian collagen glycosylation as 
up to now core glucosylation of hydroxylysine in collagen was not reported.  
 
L230 truncated protein constructs. As the L230 protein includes two do-
mains, namely the N-terminal domain homologous to human ColGalTs and 
the C-terminal domain homologous to human LH, we wanted to explore the 
enzymatic activities of these domains. To delineate the ColGlcT domain of 
L230, deletion constructs of either the N-terminal GLT25-like domain or the 
C-terminal LH-like domain were produced. While the native L230 protein is 
103.5 kDa, the truncated proteins L230 ΔC-term and L230 ΔN-term are 
70.0 kDa and 67.9 kDa, respectively. These constructs were tested in the en-
zymatic activity assay using UDP-Glc as the donor substrate. As depicted in 
figure 6, neither of the two truncated constructs was able to in vitro glucosy-
late collagen, which might be due to incorrect folding or instability of the 
truncated version of the proteins. 
 
Lysyl hydroxylase activity assay. As the L230 enzyme shows a domain with 
homology to the LH enzyme, the ability of L230 to act as a LH enzyme was 
tested. Lysine hydroxylation was tested on synthetic peptide acceptors, ei-
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ther the peptide (GIK)4 (3, 22) or the mimiviral peptide (GDK)4. The human 
lysyl hydroxylase LH1 was used as a positive control in the LH activity assay 
(20). LH1 was only able to hydroxylate the (GIK)4 peptide but not the 
mimiviral peptide (GDK)4. By contrast, the L230 enzyme did not show any 
LH activity on neither of the two peptides tested (Fig. 7). 
 
ColGlcT gene expression. Mimiviral infection of A. polyphaga has a typical 
viral development cycle (9). Newly synthesized virions accumulate in the 
cytoplasm at 8 hpi. At 24 hpi, most of the infected amoebae are lyzed and 
large amounts of infectious MIMIV particles are released in the culture me-
dium (19). The onset of RNA expression of mimiviral collagens and of en-
zymes potentially involved in collagen modification was investigated during 
infection by Northern Blot analysis. Total RNA was isolated from A. poly-
phaga at 4, 8, 16 and 24 hpi. The expression of the L230 and of the mimiviral 
collagen glycosyltransferase candidate R699 genes was compared with the 
expression of the mimiviral collagen R241 gene during mimiviral infection. 
R699 is clearly expressed at 8 hpi, while L230 is only very weakly expressed 
at this time point. Collagen expression begins 16 hpi and correlates with the 
expression of the ColGlcT L230 (Fig. 8). 
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Discussion 
Viruses are obligate intracellular parasites and depend on many cellular 
functions to complete their replication. The limited space for genetic infor-
mation requires optimized genomes, which are reduced to the essentials. 
Therefore it is remarkable that the category of large DNA viruses encode 
many proteins with similar functions to those found in the host cells. MIMIV, 
which represents the largest virus identified to date, has for example many 
genes on his own that encode enzymes involved in the translation of proteins 
or DNA repair (19). Furthermore, the MIMIV genome includes many genes 
sharing similarity with eukaryotic and prokaryotic glycosylation genes. In 
this respect, the present identification of the ColGlcT enzyme in MIMIV does 
not come as a surprise.  
In this report, we have shown that the L230 ColGlcT activity is different to 
the human ColGalT activity. Based on the knowledge from the animal colla-
gen, which is glucosylated only upon galactosylation, we expected that the 
product of the L230 ColGlcT activity assay would be Glc(α1-2)Gal(β1-O) (17). 
However, HPLC product analysis of the products from the enzymatic activ-
ity assay performed with the L230 ColGlcT revealed that Glc was directly 
linked to Hyl and not to GHyl (Fig. 5). Further analysis of the carbohydrates 
will have to confirm this finding.  
L230 did not show any LH activity on the tested acceptor peptides, even 
though L230 is homologous in its C-terminal region to the human LH3 en-
zyme. The peptide acceptors tested were chosen either from the literature 
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((GIK)4, (3, 22)) or by considering their high occurrence in MIMIV collagens 
((GDK)4). If GDK would represent the recognition sequence of L230 as the 
lysyl hydroxylase, all the mimiviral collagen would be extensively hydroxy-
lated, which seems unlikely. Other peptide sequences, which are more het-
erogeneous in their sequence, should be tested as LH acceptor peptides.  
To determine whether the GLT25-like and the LH-like domains represent 
distinct enzymatic entities, the single domains of L230 were produced in Sf9 
insect cells and tested for their ColGlcT activity. Neither the N-terminal hu-
man GLT25-like domain nor the C-terminal LH-like domain were able to act 
as ColGlcT. It might be that the truncated proteins are not correctly folded or 
do aggregate and therefore are not active as enzymes. To circumvent this 
possibility, a mutagenesis study will allow the delineation of the ColGlcT 
activity within the L230 protein. 
 The fibrils on the viral capsid are supposed to have a collagenous origin (9, 
12). Analysis of these fibrils of MIMIV would give further information about 
the mimiviral collagens. Currently it has been reported that the MIMIV ge-
nome contains eight ORFs, which encode proteins with collagen motifs. It is 
not known, if all these eight collagen motifs encoded in the MIMIV genome 
are expressed within the fibrils on the viral capsid and if these collagenous 
fibrils are indeed glycosylated. Analysis of the glycans of the MIMIV fibrils 
would give further information on the type of glycans, if MIMIV collagen 
glycans also contain Gal as seen in animal collagens and if MIMIV also has 
collagen disaccharides. This information could also help to explain the bio-
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logical relevance of glycosylated fibrils. One possible explanation could be 
that the MIMIV collagen-like proteins on the capsid might protect the virus, 
as it could work as a stable protective shield against environmental adverse 
conditions. The reported facts that MIMIV is resistant to harsh conditions as 
UV radiation, mechanical stress and elevated temperature corroborate the 
protective properties of the fibrils.  
A difference between the human ColGalT and the MIMIV ColGlcT is its sub-
cellular localization. While GLT25D1 and GLT25D2 are type II transmem-
brane proteins, L230 is a soluble enzyme. This feature would enable the use 
of the soluble recombinant L230 enzyme as an improved tool for in vitro col-
lagen glycosylation, as a soluble protein is much easier to isolate. Correctly 
glycosylated collagen is necessary for the medical application of collagen in 
humans. In fact, the application of bovine collagen and of unmodified re-
combinant human collagen has been shown to induce allergic reaction in a 
non-negligible number of treated persons. For this purpose, the soluble L230, 
which catalyzes the addition of core-Glc, has to be engineered to a ColGalT 
for use in biotechnology. From blood-group glycosyltransferases it is known 
that only a few amino acids can change the specificity of a transferase (11, 
26). Studying the domain which is responsible for the recognition of UDP-
Glc and to change it into a UDP-Gal recognition domain would give rise to a 
soluble ColGalT which can be used for in vitro glycosylation of human colla-
gen.  
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Appendix  
Supplementary Table A1: HPLC gradient 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
Solvent C 
[%] 
0.0 75 0 25
74.2 64 0 36 
78.7 64 0 36 
78.9 0 65 35 
104.0 0 65 35 
129.3 0 25 75 
135.3 0 25 75 
153.1 75 0 25 
188.9 75 0 25 
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Figure Legends 
Fig. 1: Cladogram of human ColGalT related proteins. Human ColGalT 
GLT25D1 and GLT25D2 as well as the non-active homologue CEECAM1 
were blasted against proteins of other species and aligned using the 
ClustalW algorithm. Homologous proteins were found not only in eukaryo-
tes but also in several bacteria and even in MIMIV.  
 
Fig. 2: Protein Alignment and L230 topology. (A) The protein alignment 
shows the homology of the MIMIV L230 protein to the human GLT25D1 and 
GLT25D2 in the N-terminal region and the homology of L230 to the human 
LH1, LH2 and LH3 in the C-terminal region. (B) L230 has two domains. The 
N-terminal region, shaded in grey, is homologous to the human ColGalT 
GLT25D1 and GLT25D2. The C-terminal region shows a homology with the 
human lysyl hydroxylases LH1, LH2 and LH3. 
 
Fig. 3: Enzymatic activity of MIMIV L230 protein. Mock and L230 transfected 
Sf9 cells were tested for ColGlcT and ColGalT activity on the acceptor colla-
gen type I. L230 shows a ColGlcT but not a ColGalT activity. Bars indicate 
the means of six assays. Error bars indicate the SD. 
 
Fig. 4: ColGlcT activity of L230 towards synthetic acceptor peptides. L230 
was assayed on the MIMIV collagen peptide L71 (GDVGD-Hyl-GDVGD-
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Hyl-GDVGD-Hyl-G), the human Col2A1 (GPTGVTGP-Hyl-KGARGAQGP) 
and the human ADIPOQ (GDPGLIGP-Hyl-GDIGETGVP). Bars indicate the 
means of four assays. Error bars indicate the SD. 
 
Fig. 5: ColGlcT reaction product identification. The first panel represents a 17 
amino acid standard containing the standards GHyl and GGHyl separated 
on RP-HPLC. Panel two shows a collagen type II hydrolyzate with the glyco-
sylated hydroxylysine GHyl and GGHyl. The third panel shows the radioac-
tive trace obtained after the reaction of L230 (black) with collagen type I 
compared with the radioactive trace of the reaction with mock transfected 
cells (grey). [3H]Val and [14C]Tyr were used as internal amino acid standards. 
Amino acids are marked in single-letter code. 
 
Fig. 6: ColGlcT enzymatic activity assay with truncated L230. Constructs 
bearing only the GLT25D-like domain (L230 ΔC-term) or the LH-like domain 
(L230 ΔN-term) were analyzed for their ColGlcT activity on collagen type I. 
 
Fig. 7: Lysyl hydroxylase activity of L230. The MIMIV L230 and the human 
LH1 enzymes were assayed on the acceptor peptides (GIK)4 and (GDK)4. 
Bars indicate the means of four to six assays. Error bars indicate the SD. 
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Fig. 8: Northern blotting of mimiviral enzymes and collagen. The onset of 
RNA expression of mimiviral collagens and of enzymes potentially involved 
in collagen modification was explored during mimiviral infection of A. poly-
phaga. Different infection time points were analyzed: mock, 4, 8, 16, 24 h post 
infection (hpi). The first panel shows the putative glycosyltransferase R699, 
the second one L230 and the third panel the viral collagen R241.  
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Figure 1 
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Figure 2 
 
 
GLT25D1 : TWSFDDIIVFAFSCKQAEVQMYVCNKEEYGFLPVPLRAHSTLQDEAESFMHVQLEVMVKHPPAEPSRFISAPTKTPDKMGFDEVFMINLRRRQDRRERMLRAL------QAQEIECRLVEAVDGKAMNTS : 383 
GLT25D2 : TWTFDDIIVFAFSSRQAGIQMYLCNREHYGYLPIPLKPHQTLQEDIENLIHVQIEAMIDRPPMEPSQYVSVVPKYPDKMGFDEIFMINLKRRKDRRDRMLRTL------YEQEIEVKIVEAVDGKALNTS : 384 
L230    : --------------------------------------------------------------------------------MISRTYVINLARRPDKKDRILAEFLKLKEKGVELNCVIFEAVDGN--NPE :  48 
LH2     : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
LH3     : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
LH1     : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
 
                                                                                                                                                   
GLT25D1 : QVEALGIQMLPGYRDPYHGRPLTKGELGCFLSHYNIWKEVVDRGLQKSLV-------FEDDLRFEIFFKRRLMNLMRDVEREGLDWDLIYVGRKRMQVEHPEKAVPRVRNLVEADYSYWTLAYVISLQGA : 506 
GLT25D2 : QLKALNIEMLPGYRDPYSSRPLTRGEIGCFLSHYSVWKEVIDRELEKTLV-------IEDDVRFEHQFKKKLMKLMDNIDQAQLDWELIYIGRKRMQVKEPEKAVPNVANLVEADYSYWTLGYVISLEGA : 507 
L230    : HLSRFNFK-IPNWTDLNSGKPMTNGEVGCALSHWSVWKDVVDCVENGTLDKDCRILVLEDDVVFLDNFMERYQTYT---SEITYNCDLLYLHRKPLNPYTETKISTHI---VKPNKSYWACAYVITYQCA : 171 
LH2     : ---------------------------------------------------------------------------------------------------------------MGGCTVKPQLLLLALVLHP :  19 
LH3     : ---------------------------------------------------------------------------------------------------------------MTSSGPGPRFLLLLPLLLP :  19 
LH1     : --------------------------------------------------------------------------------------------------------------------MRPLLLLALLGWLL :  14 
                                                                                                                                                   
                                                                                                                                                   
GLT25D1 : RKLLAAEPLSKMLPVDEFLPVMFDKHPVSEYKAHFSLRNLHAFSVEPLLIYPTHYTGDDGYVSDTETSVVWNNE-HVKTDWDRAKSQKMREQQALSREAKNSDVLQSP--LDSA-ARDEL---------- : 622 
GLT25D2 : QKLVGANPFGKMLPVDEFLPVMYNKHPVAEYKEYYESRDLKAFSAEPLLIYPTHYTGQPGYLSDTETSTIWDNE-TVATDWDRTHAWKSRKQSRIYSNAKNTEALPPPTSLDTVPSRDEL---------- : 626 
L230    : KKFMNANYLENLIPSDEFIPIMHGCNVYGFEKLFSNCEKIDCYAVQPSLVKLTSNAFND---SETFHSGSYVPSNKFNFDTDKQFRIVYIGPTKGNSFHRFTEYCKLYLLPYKV--IDEKETNDFVSLRS : 296 
LH2     : WNPCLGADSEKPSSIPTDKLLVITVATKESDGFHRFMQSAKYFN-YTVKVLGQGEEWRGGDGINSIGGGQKVRLMKEVMEHYADQDDLVVMFTECFDVIFAGGPEEVLKKFQKANHKVVFAADGILWPDK : 148 
LH3     : PAASASDRPRGRDPVNPEKLLVITVATAETEGYLRFLRSAEFFN-YTVRTLGLGEEWRGGDVARTVGGGQKVRWLKKEMEKYADREDMIIMFVDSYDVILAGSPTELLKKFVQSGSRLLFSAESFCWPEW : 148 
LH1     : LAEAKG------DAKPEDNLLVLTVATKETEGFRRFKRSAQFFN-YKIQALGLGEDWN-VEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDR : 136 
                                                                                                                                                   
                                                                                                                                                   
GLT25D1 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
GLT25D2 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
L230    : ELQSLSEQDLNTTLMLVVSVNHNDFCNTIPCAPTNEFIDKYKQLTTDTNSIVSAVQNGTNKTMFIGWANKISEFINHYHQKLTESNAETDINLANLLLISSISSDFNCVVEDVEGNLFQLINEESDIVFS : 426 
LH2     : RLADKYPVVHIGKRYLNSGGFIGYAPYVNRIVQQWNLQDNDDDQLFYTKVYIDPLKREAINITLDHKCKIFQTLNGAVDEVVLKFENGKARAKNTFYETLPVAINGNGPTKILLNYFGNYVPNSWTQDNG : 278 
LH3     : GLAEQYPEVGTGKRFLNSGGFIGFATTIHQIVRQWKYKDDDDDQLFYTRLYLDPGLREKLSLNLDHKSRIFQNLNGALDEVVLKFDRNRVRIRNVAYDTLPIVVHGNGPTKLQLNYLGNYVPNGWTPEGG : 278 
LH1     : RLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETG : 266 
 
 
GLT25D1 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
GLT25D2 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
L230    : TTTSRVNNKLGKTPSVLYANSDSSVIVLNKVENYTGYGWNEYYGYHVYPVKFDVLPKIYLSIRIVKNANVTKIAETLDYPKELITVSISRSEHDSFYQADIQKFLLSGADYYFYISGDCIITRPTILKEL : 556 
LH2     : CTLCEFDTVDLSAV--DVHPNVSIGVFIEQPTPFLPRFLDILLTLDYPKEALKLFIHNKEVYHEKDIKVFFDKAKHEIKTIKIVGPEENLSQAEARNMGMDFCRQDEKCDYYFSVDADVVLTNPRTLKIL : 406 
LH3     : CGFCNQDRRTLPGG--QPPPRVFLAVFVEQPTPFLPRFLQRLLLLDYPPDRVTLFLHNNEVFHEPHIADSWPQLQDHFSAVKLVGPEEALSPGEARDMAMDLCRQDPECEFYFSLDADAVLTNLQTLRIL : 406 
LH1     : CTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLL : 396 
                                                                                                                                                 
 
GLT25D1 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
GLT25D2 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
L230    : LELNKDFVGPLMRKGTESWTNYWGDIDPSNGYYKRSFDYFDIIGRDRVGCWNVPYLASVYLIKKSVIEQVPNLFTENSHMWNGSNIDMRLCHNLRK---------------------NNVFMYLSNLRPY : 665 
LH2     : IEQNRKIIAPLVTRHGKLWSNFWGALSP-DGYYARSEDYVDIVQGNRVGVWNVPYMANVYLIKGKTLR--SEMNERNYFVRDKLDPDMALCRNAREMTLQREKDSPTPETFQMLSPPKGVFMYISNRHEF : 533 
LH3     : IEENRKVIAPMLSRHGKLWSNFWGALSP-DEYYARSEDYVELVQRKRVGVWNVPYISQAYVIRGDTLR--MELPQRDVFSGSDTDPDMAFCKSFRD---------------------KGIFLHLSNQHEF : 512 
LH1     : IQQNKNVIAPLMTRHGRLWSNFWGALSA-DGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALR--GELQSSDLFHHSKLDPDMAFCANIRQ---------------------QDVFMFLTNRHTL : 502 
                                                                                                                                                 
GLT25D1 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
GLT25D2 : ---------------------------------------------------------------------------------------------------------------------------------- :   - 
L230    : GHIDDSINLEVLSGVPTEVTLYDLPTRKEEWEKKYLHPEFLSHLQNFKDFDYTEICNDVYSFPLFTPAFCKEVIEVMDKANLWSKGGDSYFDPRIGGVESYPTQDTQLYEVGLDKQWHYVVFNYVAPFVR : 795 
LH2     : GRLLSTANYNTSHYNNDLWQIFENPV---DWKEKYINRDYSKIFT---ENIVEQPCPDVFWFPIFSEKACDELVEEMEHYGKWS-GGKHHDSRISGGYENVPTDDIHMKQVDLENVWLHFIREFIAPVTL : 656 
LH3     : GRLLATSRYDTEHLHPDLWQIFDNPV---DWKEQYIHENYSRALE--GEGIVEQPCPDVYWFPLLSEQMCDELVAEMEHYGQWS-GGRHEDSRLAGGYENVPTVDIHMKQVGYEDQWLQLLRTYVGPMTE : 636 
LH1     : GHLLSLDSYRTTHLHNDLWEVFSNPE---DWKEKYIHQNYTKALA---GKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWS-LGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFLLEYIAPMTE : 625 
                                                                                                                      
 
 
GLT25D1 : ------------------------------------------------------------------------------------------------------ :   - 
GLT25D2 : ------------------------------------------------------------------------------------------------------ :   - 
L230    : HLYNNYKTKDIN-LAFVVKYDMERQSELAPHHDSSTYTLNIALNEYGKEYTAGGCEFIRHKFIWQGQKVGYATIHAGKLLAYHRALPITSGKRYILVSFVN- : 895 
LH2     : KVFAGYYTKGFALLNFVVKYSPERQRSLRPHHDASTFTINIALNNVGEDFQGGGCKFLRYNCSIESPRKGWSFMHPGRLTHLHEGLPVKNGTRYIAVSFIDP : 758 
LH3     : SLFPGYHTKARAVMNFVVRYRPDEQPSLRPHHDSSTFTLNVALNHKGLDYEGGGCRFLRYDCVISSPRKGWALLHPGRLTHYHEGLPTTWGTRYIMVSFVDP : 738 
LH1     : KLYPGYYTRAQFDLAFVVRYKPDEQPSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP : 727   
 
MISRTYVINLARRPDKKDRILAEFLKLKEKGVELNCVIFEAVDGNNPEHL   50 
SRFNFKIPNWTDLNSGKPMTNGEVGCALSHWSVWKDVVDCVENGTLDKDC  100 
RILVLEDDVVFLDNFMERYQTYTSEITYNCDLLYLHRKPLNPYTETKIST  150 
HIVKPNKSYWACAYVITYQCAKKFMNANYLENLIPSDEFIPIMHGCNVYG  200 
FEKLFSNCEKIDCYAVQPSLVKLTSNAFNDSETFHSGSYVPSNKFNFDTD  250 
KQFRIVYIGPTKGNSFHRFTEYCKLYLLPYKVIDEKETNDFVSLRSELQS  300 
LSEQDLNTTLMLVVSVNHNDFCNTIPCAPTNEFIDKYKQLTTDTNSIVSA  350 
VQNGTNKTMFIGWANKISEFINHYHQKLTESNAETDINLANLLLISSISS  400 
DFNCVVEDVEGNLFQLINEESDIVFSTTTSRVNNKLGKTPSVLYANSDSS  450 
VIVLNKVENYTGYGWNEYYGYHVYPVKFDVLPKIYLSIRIVKNANVTKIA  500 
ETLDYPKELITVSISRSEHDSFYQADIQKFLLSGADYYFYISGDCIITRP  550 
TILKELLELNKDFVGPLMRKGTESWTNYWGDIDPSNGYYKRSFDYFDIIG  600 
RDRVGCWNVPYLASVYLIKKSVIEQVPNLFTENSHMWNGSNIDMRLCHNL  650 
RKNNVFMYLSNLRPYGHIDDSINLEVLSGVPTEVTLYDLPTRKEEWEKKY  700 
LHPEFLSHLQNFKDFDYTEICNDVYSFPLFTPAFCKEVIEVMDKANLWSK  750 
GGDSYFDPRIGGVESYPTQDTQLYEVGLDKQWHYVVFNYVAPFVRHLYNN  800 
YKTKDINLAFVVKYDMERQSELAPHHDSSTYTLNIALNEYGKEYTAGGCE  850 
FIRHKFIWQGQKVGYATIHAGKLLAYHRALPITSGKRYILVSFVN       895 
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Figure 4 
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Figure 5 
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Figure 7 
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Figure 8 
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3 Discussion 
 
Glycosylation is a ubiquitous modification of collagen. Up to now, only the 
LH3 enzyme has been reported to mediate collagen glycosylation quite inef-
ficiently. In the present work, we have identified two collagen glycosyltrans-
ferase enzymes, GLT25D1 and GLT25D2, as well as the non-active protein 
CEECAM1, which share a high degree of sequence identity to each other. 
Tissue Northern Blotting of the human ColGalT GLT25D2 showed that the 
expression of this enzyme is confined to neuronal tissue. As neuronal tissue 
only expresses collagen type IV in small amounts in the cerebrovascular 
basal lamina as part of the blood brain barrier (126-128), and collagen XVII 
as possible anchor of neurons to their substratum in various neuronal regions 
(129) the question arises on the main substrate of GLT25D2 in the brain. As 
GLT25D2 is also able to glycosylate non-collagenous proteins, which contain 
a collagen like domain, acetylcholinesterase could be a possible substrate. 
Acetylcholinesterase is responsible for the rapid hydrolysis of the neuro-
transmitter acetylcholine at nicotinic cholinergic synapses terminating muscle 
contraction. The asymmetric acetylcholinesterase consists of one to three 
catalytic tetramers linked to a collagen-like tail, the ColQ protein. ColQ con-
tains a collagen-like domain, which is characterized by Gly-X-Y repeats and 
forms a collagen triple helix. The collagen-tail of acetylcholinesterase is re-
sponsible for the anchoring of the enzyme to the basal lamina of the neuro-
muscular junction (130-132). The ColQ of acetylcholinesterase, which is 
located at the neuronal junction, could be a good target for the GLT25D2 
activity. This would mean that beside collagens expressed in the neuronal 
tissue, also non-collagenous proteins could be targets of GLT25D2.  
As collagen functions as a central unit of the connective tissue, the question 
of the presence of collagen in simple organisms is of interest. Not a long time 
ago, MIMIV has been detected as a unique organism being clearly a virus but 
also showing features never seen before in viruses. In the present work, we 
have characterized the mimiviral ColGlcT L230 protein. It appears that colla-
gen glycosylation in MIMIV is different than in animal collagens. In animal, 
collagens either Gal or glucosylgalactose are attached to Hyl but in our in 
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vitro enzymatic activity assay, we could glucosylate Hyl in different collagen 
molecules, which was never described up to now. It was suggested that 
MIMIV virions also consist of collagenous proteins (133, 134). The fibrils sur-
rounding the virus capsid might be post-translationally modified by virus en-
coded enzymes. These glycosylated capsid proteins possibly contribute to 
the high resistance of MIMIV to harsh conditions outside the host cell, like 
elevated temperature, mechanical stress and UV radiation. 
Even though the MIMIV ColGlcT has been identified based on sequence ho-
mology to the human ColGalT, the mimiviral ColGlcT catalyzes the transfer of 
UDP-Glc and not UDP-Gal onto collagen as would be expected. From the 
ABO blood group glycosyltransferases, it is known that only a few amino ac-
ids can determine the substrate specificity of a glycosyltransferase (135). The 
GalNAc-transferase of the blood group A and the Gal-transferase of the 
blood group B differ in only four amino acids on the whole sequence. Of 
these four amino acids only one single amino acid residue is responsible for 
the biosynthesis of the different carbohydrates of blood group A and blood 
group B (135). As only one single amino acid can determine the substrate 
specificity of a glycosyltransferase, this could explain the different properties 
of the MIMIV ColGlcT L230 and of the human ColGalT, although they share a 
high degree of sequence similarity.  
Currently, the function of the collagen glycosylation is not understood, al-
though the glycan structure of collagen was already solved in 1967 (95). The 
glycans might be involved in the lateral packing of the collagen molecule into 
fibrils, which might influence the diameter of the collagen fibrils (102). The 
glycans may play an important role in the secretion of the collagen mole-
cules, the glycans may act as a targeting signal for proper secretion of the 
collagen fibrils into the extracellular matrix. This was demonstrated for the 
non-collagenous proteins ADIPOQ and MBL, which are not properly oli-
gomerized and secreted (25, 103). However, to completely understand the 
function of collagen glycosylation, it is important to identify all enzymes in-
volved in this process. The identification and characterization of the two hu-
man ColGalTs GLT25D1 and GLT25D2 is the first step in understanding 
collagen glycosylation and it might facilitate genetic investigations to further 
elaborate the role of collagen glycosylation, also in respect to connective tis-
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sue disorders. But to fully understand collagen glycosylation, the second en-
zyme, the ColGlcT, which is also involved in this process, has to be identified 
as well. Based on homology blast searches against known α-glucosyltrans-
ferases several candidates for human ColGlcTs were already tested (data 
not shown). However, as the ColGlcT candidates did not show any ColGlcT 
activity, the human ColGlcT still remains unknown. 
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4 Abbreviations 
 
3Hyp 3-hydroxyproline 
4Hyp 4-hydroxyproline 
ADIPOQ adiponectin 
BCS Brittle Cornea Syndrome 
CDG congenital disorders of glycosylation 
CMP cytidine monophosphate 
ColGalT Collagen galactosyltransferase 
ColGlcT Collagen glucosyltransferase 
CRD carbohydrate recognition domain 
EDS Ehlers-Danlos-Syndrome 
EGF epidermal growth factor 
ER Endoplasmic Reticulum 
Fuc fucose 
Gal galactose 
GalNAc N-acetylgalactosamin 
GalT galactosyltransferase 
Glc glucose 
GlcA glucuronic acid 
GlcNAc N-acetylglucosamin 
GMP guanosine monophosphate 
GT glycosyltransferase 
HMW high molecular weight 
Hyl Hydroxylysine 
Hyp Hydroxyproline 
LH lysylhydroxylase 
LLO lipid-linked oligosaccharide 
Man mannose 
MBL Mannose binding lectin 
NDP nucleotide diphosphate 
NMP nucleotide monophosphate 
OI Osteogenesis Imperfecta 
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P3H prolyl-3-hydroxylase 
P4H prolyl-4-hydroxylase 
Sia sialic acid 
UDP uridine diphosphate 
UDP uridine monophosphate 
Xyl Xylose 
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